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1. Introduction 
1.1 Scientific Relevance 
Stroke, by definition, is a sudden loss of neurologic function resulting from 
focal disturbance of cerebral blood flow due to ischemia or hemorrhage. Depending 
on the duration of the cerebrovascular disturbance, stroke can cause permanent 
neurologic damage, disability, or death (Shichita et al., 2012). A transient ischemic 
attack (TIA; stroke symptoms lasting < 1 hr) may not cause neurologic damage but is 
strongly associated with a risk for subsequent stroke within the next 90 days. Stroke 
by itself is the second single most common cause of death in Europe: accounting for 
almost 1.1 million deaths in Europe each year. This is 10% of all deaths in men and 
15% of all deaths in women.  
 
 
Figure 1.1: Classifications of Stroke. 
Ischemic stroke accounts for 80% and Hemorrhagic Stroke accounts for 20% of all stroke 
incidences Source: (http://www.ehnheart.org/cvd-statistics.html).  
 
 Ischemic stroke accounts for 85% of all strokes. There are two forms of 
ischemic stroke: focal and global ischemia. Focal ischemia is the result of lack of 
blood flow to an area of the brain due to a blood clot, known also as embolism 
(Figure 1.1). Strokes may occur anywhere in the brain, including the cerebrum, 
brainstem, and the cerebellum. The most common area of infarct is blockage of the 
middle cerebral artery, which affects blood supply mainly to the striatum and 
forebrain. Global ischemia is the disruption of blood flow to the entire brain. Global 
ischemia can be the result of a heart attack, drowning, suffocation, or any sort of 
blockage that results in lack of blood flow to the head. 
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An ischemic stroke can be permanent or temporary, in which case the blood 
clot is eventually broken down, and reperfusion takes place. Neurons need a constant 
supply of oxygen and glucose, which is carried by blood. Without oxygen and 
glucose, neurons cannot produce energy and die. Cell death after ischemic stroke is 
thought to be both due to both apoptotic and necrotic pathways within the cells (Unal-
Cevik et al., 2004). The occlusion of the brain blood vessel during stroke initiates the 
ischemic cascade, causing the activation of many signaling pathways that compromise 
cell survival and function, such as glutamate mediated excitotoxicity, Ca2+ overload, 
oxidative stress and blood brain barrier (BBB) dysfunction, inflammation and cell 
death (Mehta et al., 2007) . 
The only FDA-approved treatment for ischemic stroke is tissue plasminogen 
activator (tPA), which has a narrow time window of only approximately 4.5 hours 
after the onset of stroke symptoms. tPA acts as a thrombolytic agent through the 
activation of plasminogen to plasmin which degrades the fibrin clot . Approximately 
only 3-5% of all patients that suffer a stroke benefit from tPA, mainly due to the 
narrow therapeutic window (Hacke et al., 2008; Martin-Schild, 2012). The lack of 
available therapies and the devastating effects of these diseases compel researchers 
and clinicians to find more effective treatments (Moskowitz et al., 2010). 
 
1.2. Blood Brain Barrier (BBB) and Stroke 
The BBB is localized at the interface between the blood and the cerebral 
tissue. The selective nature of this barrier is vital to protect the CNS and maintain its 
vital functions. The BBB is comprised of endothelial cells, which prevent the 
movement of molecules into the brain. The BBB consists of not only endothelial cells 
but also astrocytic end-feet and tight junctions, which support the selective 
permeability of this barrier (Figure 1.2). Molecules larger than 400 daltons are unable 
to cross the BBB.  Brain endothelial cells differ significantly from non-brain ECs by 
(i) the absence of fenestration correlating with the presence of intercellular tight 
junctions (TJs), (ii) the low level of non specific transcytosis (pinocytosis) and 
paracellular diffusion of hydrophilic compounds, (iii) a increased mitochondria, 
associated with a strong metabolic activity and (iv) the polarized expression of 
membrane receptors and transporters which are responsible for the active transport of 
blood-borne nutrients to the brain or the efflux of potentially toxic compounds from 
the cerebral to the vascular compartment. 
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Figure 1.2: Structure of the Blood brain barrier 
Morphology of the brain microvascular capillary endothelium and the surrounding region. 
Modified from Expert reviews in molecular medicine ©2003 Cambridge University Press 
(http://journals.cambridge.org/fulltext_content/ERM/ERM5_15/S1462399403006252sup001.
pdf) 
 
Acute obstruction of cerebral blood vessel by clot formation triggers a 
complex series of cellular and molecular events in the brain parenchyma (membrane 
depolarization of neurons and astrocytes, release of excitatory amino acids and K+ 
ions in interstitial fluids, increase of intracellular Ca2+ levels), ultimately leading to 
dramatic cell damage within hours. Up-regulation of the matrix metalloproteinases 
(MMP)-2 and -9, as well as of the vascular endothelial growth factor (VEGF) are 
closely associated with BBB disruption (Yang et al., 2007; Bauer et al., 2010). 
Release of oxidants, proteolytic enzymes and inflammatory cytokines were shown to 
alter the BBB permeability properties, leading to brain edema formation (Dirnagl et 
al., 1999).  
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BBB dysfunction under ischemic conditions results in an increased 
paracellular permeability, which contributes to cerebral edema, hemorrhagic 
transformation, and increased mortality. Various mechanisms which occur is multiple 
phases, contribute to the ischemic damage of the BBB. Initially, the dissolution of the 
endothelial basal lamina takes place and this is rapidly followed by an increase in 
BBB permeability. After reperfusion, a biphasic increase of BBB permeability may 
occur. The multi-phasic phenomenon of this permeability change is determined by 
various factors, including the duration of ischemia and degree of reperfusion.  
The increase of paracellular permeability is generally associated with the 
alteration of tight-junction protein expression and/or the redistribution of tight-
junction protein along the cellular membrane. It has been shown that a reduction in  
Trans-Endothelial Electrical Resistance (TEER) is accompanied by a decreased 
claudin-5 expression under the hypoxic conditions, whereas hypoxia induced increase 
of paracellular permeability has been observed along with the disruption of occludin, 
ZO-1, and ZO-2 membrane localization (Mark and Davis, 2002; Koto et al., 2007).  
In response to brain ischemia, accumulated bradykinin, VEGF, and thrombin 
initiate the increase of intracellular calcium concentration, whose primary effect in the 
endothelial cells is the activation of calcium/calmodulin-dependent myosin light chain 
kinase (MLCK) (Goeckeler and Wysolmerski, 1995), inducing actin reorganization, 
changes of cell morphology, and increased BBB paracellular permeability. Oxidative 
stress is also an early stimulus for BBB disruption and triggers the cellular release of 
MMP-9 from neurons, astrocytes, pericytes, and endothelial cells, resulting in 
digestion of the endothelial basal lamina. In the later phase, severe BBB damage 
resulting from more complicated mechanisms appears, such as induction of pro-
inflammatory cytokines, followed by chemokines and adhesion molecules expression 
on the activated endothelium.  
The expression of cytokines and adhesion molecules precedes the infiltration 
of leukocytes, which, together with activated microglia, further enhances the 
inflammatory responses and the production of toxic free radicals (Huang et al., 2006). 
The damaged BBB allows leakage of blood constituents into the brain parenchyma 
(Lo et al., 2003). Extravasation of high molecular weight components, which is 
followed by water due to osmosis, leads to vasogenic edema and intracranial 
hypertension. In particular, the extravasation of red blood cells may lead to 
hemorrhagic transformation in the brain. 
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1.3 Astrocytes in Ischemic Brain 
Astrocytes are the most abundant glial cells within the central nervous system 
(CNS) and comprise of approximately 50% of the total number of cells in the cerebral 
cortex. These cells can be identified by staining for glial fibrillary acidic protein 
(GFAP), revealing star shaped morphologies. Astrocytes are classically divided into 
three major types according to their morphology and spatial organization, 
protoplasmic astrocytes in grey matter, fibrous astrocytes in white matter and radial 
astrocytes surrounding ventricles (Ransom and Ransom, 2012).  
In response to different types of stimulation, astrocytes are known to release 
various factors including brain-derived neurotrophic factor (BDNF), nerve growth 
factor (NGF), glial-cell-line-derived neurotrophic factor (GDNF), transforming 
growth factor- β1 (TGF-β1), neurotrophin (NT), nitric oxide (NO), reactive oxygen 
species (ROS), interleukins (ILs) and tumor necrosis factor-α (TNF-α). Astrocytes 
express chemokines and cytokines in response to inflammatory stimulators. Other 
hand, they prevent excessive inflammatory responses of microglia thus contributing to 
inflammation positively or negatively (Lin et al., 2006). The primary response of the 
astrocytes following cerebral ischemia is likely to be important for neuronal 
protection. Astrocyte activation process is commonly known as reactive gliosis. The 
reactive astrocyte morphology is altered accompanied by differential expression of 
hundreds of genes compared to the non-reactive astrocyte (Eddleston and Mucke, 
1993). Astrocyte reactivity is generally associated with microglial reactivity and, in 
some cases, leukocyte recruitment. 
Activated astrocytes migrate to the injured area and contribute to glial scar 
formation. Glial scars may act as a barrier by sealing off the injured tissue from the 
healthy tissue. Axons cannot regenerate beyond glial scars, which may inhibit 
neuronal recovery processes after damage as shown by Silver et. al. (Silver and 
Miller, 2004). Astrocytes have been suggested to play a detrimental role following 
ischemia as the gap junctions may remain open (Martinez and Saez, 2000), allowing 
substances such as pro-apoptotic factors to spread through the syncytium thereby 
expanding the size of the infarct (Lin et al., 1998). 
In-vitro studies have provided substantial insight into the mechanisms 
governing the survival of astrocytes following simulated ischemia. It has been shown 
that astrocytes are generally more resistant than neurons to oxygen-glucose 
deprivation (OGD) (Sochocka et al., 1994). Most neurons in a cortical astrocytic-
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neuronal co-culture show signs of cell death after 60-70 min of OGD while astrocyte 
cultures require several hours to develop such extensive damage (Almeida et al., 
2002). However, it appears that not all groups of astrocytes are similarly resistant to 
ischemic insults. The in-vitro studies have also provided a better understanding of 
what mechanisms influence astrocytic cell death. For example, a combination of 
hypoxia and acidosis has been found to be very effective in killing astrocytes (Giffard 
et al., 1990; Swanson et al., 1997; Bondarenko and Chesler, 2001).  
 
1.4. Ischemia Reperfusion Injury in Stroke 
During ischemia, cell death/ necrosis occurs due to energy depletion and loss 
of O2 supply. The recovery of energy metabolism during the initial 20 minutes of 
reperfusion is accompanied by a restoration of the distribution of ions to near their 
pre-ischemic state. During reperfusion after ischemia, while restoration of oxygen and 
glucose supply reinstates the oxidative phosphorylation that helps to normalize energy 
demanding physiologic processes (Aronowski et al., 1997), a parallel cascade of 
deleterious biochemical processes can be triggered that may paradoxically antagonize 
the beneficial effect of reperfusion and have been summarized in Figure 1.3. Thus, 
reperfusion injury is the tissue damage caused when blood supply returns to the tissue 
after a period of ischemia or lack of oxygen (Sari et al., 2013). This phenomenon was 
observed in the middle cerebral artery occlusion model (MCAO, a model mimicking 
clinical stroke). In this study, they observed that rats with permanent occlusion 
resulted in smaller infarct volume than rats with 2 h occlusion followed by 24 h 
reperfusion. Multiple studies and reviews have described the mechanisms by which 
leads to injury. In brief, during reperfusion, activated leukocytes interact with 
endothelial cells and plug capillaries. This is followed by disruption of BBB through 
the release of neutrophil-derived oxidants, proteolytic enzymes, which extravasate 
from capillaries and infiltrate brain tissue releasing cytokines which then mediate 
inflammation (Pan et al., 2007). Also the plugging of capillaries results in secondary 
cerebral ischemia. 
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Figure 1.3: Scheme of events following ischemia reperfusion injury.  
Ischemia reperfusion affects endothelial function, leads to vasoconstriction and infiltration of 
leukocytes and neutrophils which further enhances inflammation and cell death, Modified 
from (Pan et al., 2007) 
 
Once the leukocytes infiltrate the parenchyma, they release various chemical 
mediators like leukotrienes, and prostaglandins, reactive oxygen species (ROS), 
resulting in increased microvascular permeability, edema, thrombosis and 
parenchymal cell death (Pan et al., 2007). Platelets are known to play a synergistic 
role with leukocytes in reperfusion injury. Multiple mouse and clinical studies suggest 
that platelets are activated after cerebral ischemia and reperfusion. Activated platelets 
also release a variety of biochemical mediators which result in further tissue damage 
(del Zoppo, 1998). Complement activation has also been described to be an important 
component of reperfusion injury (Arumugam et al., 2009). Complement activation 
results in the formation of several inflammatory mediators which enhance the 
reperfusion injury. Studies have also shown that hyperperfusion may contribute to the 
development of reperfusion injury by causing brain edema or hemorrhage 
(Arumugam et al., 2009). Thus, breakdown of the BBB during cerebral reperfusion 
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may lead to the development of vasogenic edema, hemorrhagic transformation and 
infarction.  
 
1.5. Inflammation in ischemic stroke 
Inflammation is a defense reaction against diverse insults that serves to 
remove noxious agents and to limit their detrimental effects. Ischemia initiates a 
complex process in which inflammation contributes to stroke-related brain injury 
(Huang et al., 2006). Ischemia leads to the activation of microglia and astrocytes with 
subsequent production of inflammatory mediators. Cytokines stimulate the expression 
of adhesion molecules which mediate the adherence and extravasation of neutrophils 
and monocytes into the ischemic tissue (Wang et al., 2007).  The pattern of cytokine 
inflammation response differs depending on stroke type and localization. IL-1β is an 
endogenous pyrogen which centrally contributes to an exacerbation of neuronal loss 
(Rothwell and Luheshi, 2000).  IL-1β also contributes to the activation and 
proliferation of microglia and astrocytes. It has been shown that IL-1β induces edema 
formation and primes the endothelium for leukocyte adherence (Rothwell, 2003; del 
Zoppo, 2009). TNF-α like IL-1 β shows a biphasic release pattern with a first peak 1-3 
hours and a second peak 24-36 hours after an ischemic insult (Hosomi et al., 2005; 
Nilupul Perera et al., 2006; Pan and Kastin, 2007). Activated microglia and 
macrophages are major producers of soluble TNF-α within the first 6 hours after 
cerebral ischemia (Clausen et al., 2008). Yang et al showed that inhibition of TNF-α 
attenuates infarct volume and ICAM‐1 expression in ischemic mouse brain (Yang et 
al., 1998).  TNF-α stimulates apoptosis of endothelial cells contributing to vasogenic 
edema and, concomitant BBB breakdown, infiltration of circulatory inflammatory 
cells are stimulated (Christov et al., 2004). IL-6 is detected 4 hours after stroke onset, 
with peak concentrations after a day. Activated microglia, followed by astrocytes, 
neurons and invading cells of the immune system, comprise the main source for IL-6 
(Amantea et al., 2009). Recently however, Gertz et al showed that IL-6 produced 
locally by resident brain cells promotes post-stroke angiogenesis and thereby affords 
long-term histological and functional protection (Gertz et al., 2012).  
IL-10 is constitutively expressed anti-inflammatory cytokine with peak levels 
3 days after stroke onset. It is primarily produced by activated microglia and 
astrocytes (Wang et al., 2007; Ceulemans et al., 2010). IL-10 reduces pro-
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inflammatory responses after ischemic stroke primarily by acting on glia and 
endothelium (Ceulemans et al., 2010; Sharma et al., 2011). Sharma et al reported that 
IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 
pathways (Sharma et al., 2011). After stroke, intracellular adhesion molecule (ICAM) 
-1 and -2, vascular adhesion molecule (VCAM)-1 and platelet endothelial cell 
adhesion molecule (PECAM)-1 contribute to the inflammatory responses by attaching 
neutrophils and monocytes more tightly to the endothelial wall for facilitating and 
even stimulating diapedesis through the vessel wall to the site of injury (Ceulemans et 
al., 2010). It has been previously reported that the increases in ICAM-1 and VCAM-1 
after stroke are influenced by IL-1β and TNF-α (Frijns and Kappelle, 2002). VCAM-1 
is known to mediate the adhesion of lymphocytes, monocytes, eosinophils, and 
basophils to vascular endothelium as well as function in leukocyte-endothelial cell 
signal transduction (Supanc et al., 2011). 
 
1.6. Glutamate excitotoxicity in Stroke 
Glutamate released at the synapses can induce astrocytic exocytosis of 
glutamate, modulating the activity and strength of the synapse (Bezzi et al., 2004; Liu 
and Neufeld, 2004). A large proportion of the glutamate taken up by the astrocytes is 
converted to glutamine by an enzyme, glutamine synthethase (GS), exclusively 
localized in astrocytes which is up-taken by neurons thus maintaining 
neurotransmitter pool (Martinez-Hernandez et al., 1977).  
Excitotoxicity is the pathological process by which neurons are damaged and 
killed by the overreactions of receptors for the excitatory neurotransmitter glutamate, 
such as the N-Methyl-D-aspartate (NMDA) receptor and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPA) receptor (White et al., 2000) 
(Figure 1.4). In stroke, excitotoxicity is a determining factor in the extent of the 
resulting lesion. Following a stroke, there is a disruption of ionic gradients across 
membranes (Nakka et al., 2008). This disruption causes an increase in extracellular K+ 
and an influx of Na+, Cl- and Ca2+ in the cell.  The extracellular K+ triggers 
depolarization and reversal of the amino acid transporters which results in a massive 
release of glutamate.  
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Figure 1.4: Example of an NMDA receptor.  
When glutamate/ NMDA binds to this receptor, it promotes the excessive influx of Ca2+ and 
Na+ into the cell which eventually leads to excitotoxic injury. Adapted from 
http://www.medical-horizons.net 
 
The binding of glutamate to NMDA promotes excessive Ca2+ influx which 
triggers a range of downstream phospholipases and proteases that degrade membranes 
and proteins which in turn compromises cellular integrity (Mehta et al., 2007).  The 
excitatory amino acid glutamate is released in large quantities during ischemia, and 
the removal of this neurotransmitter,  predominantly accomplished by astrocytes, is 
important for neuronal survival in the post-ischemic tissue (Romera et al., 2004). 
 
1.7. Apoptosis after ischemic stroke 
Caspase-3 has been widely studied as a key mediator of apoptosis in animal 
models of ischemic stroke. It was shown that there is up-regulation of caspase-3 
mRNA, caspase-3 and its cleavage products in rat brain immediately after the onset of 
focal ischemia (Namura et al., 1998; Asahi et al., 1999).  Both genetic disruption and 
pharmacological inhibition of caspases have been found to have a strong 
neuroprotective effect in experimental stroke (Fink et al., 1999; Harukuni and 
Bhardwaj, 2006). It has been shown that oxygen glucose deprivation injury caused 
apoptotic cell death, induced cytochrome C release from mitochondria and caspase-3 
activation, decreased mitochondrial membrane potential, and increased levels of pro-
apoptotic Bax translocated to the mitochondrial membrane in PC12 neural cells, all of 
Chapter 1. Introduction 
_____________________________________________________________________ 
 - 11 - 
which were reversed by overexpression of Bcl-2 (Koubi et al., 2005). Zhao et. al. 
demonstrated that Bcl-2 overexpression protects against neuron loss within the 
ischemic margin following experimental murine stroke and inhibits cytochrome c 
translocation and caspase-3 activity (Zhao et al., 2003). Thus, various studies have 
demonstrated the vital role of Bcl-2 in providing neuroprotection against ischemic 
event (Soane and Fiskum, 2005).  
 
 
Figure 1.5: An overview of pathophysiology of ischemic stroke. 
Ischemia in the brain leads to a cascade of changes through apoptosis, inflammation and 
excitotoxicity which culminate into cell death and morbidity. Modified from (Harukuni and 
Bhardwaj, 2006) 
 
 
1.8. Role of Akt survival signaling pathway in Stroke  
Akt was originally identified as a cellular counterpart of the oncogene derived 
from murine AKT8 retrovirus. The same gene product was independently isolated as 
a protein kinase related to protein kinase A and C and was therefore named as protein 
kinase B (PKB) or RAC (related to protein kinase A and C) (Neary et al., 2005) (Hu 
et al., 2005; Zhao et al., 2006). The phosphoinositide-3-kinase/Akt cell survival 
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signaling pathway has been increasingly researched in the field of stroke (Zhao et al., 
2006; Arai and Lo, 2010). Akt activity has been suggested to be upregulated by 
phosphorylation through the activation of receptor tyrosine kinases by growth factors. 
Although the upstream signaling components phosphoinositide-dependent protein 
kinase (PDK)1 and integrin linked kinase enhance the activity of Akt, phsophatase 
and tensin homolog deleted on chromosome 10 (PTEN) decreases it. Upon activation, 
Akt phosphorylates a wide array of molecules, including glycogen synthase kinase3β 
(GSK3β), forkhead homolog in rhabdomyosarcoma (FKHR), and Bcl-2-associated 
death protein, thereby blocking mitochondrial cytochrome c release and caspase 
activity (Zhao et al., 2005; Endo et al., 2006). Generally, the level of Akt 
phosphorylation at site Ser 473 (p-Akt) transiently increases after focal ischemia. 
Numerous compounds have been demonstrated to reduce ischemic damage, possibly 
by up regulating p-Akt (Zhao et al., 2006; Li et al., 2008; Lan et al., 2013). It has been 
reported that effective recruitment of Akt by appropriate survival signals may lead to 
activation of Mdm2, inactivation of p53, and eventually inhibition of p53-dependent 
apoptosis (Gottlieb et al., 2002; Ogawara et al., 2002; Liu, G. P. et al., 2012). Taken 
together, attenuation of the Akt pathway dysfunction could contribute to neuronal and 
astrocytic survival after ischemic stroke. 
The p53 tumor suppressor gene encodes a nuclear phosphoprotein that 
functions as a key regulator of cell cycle progression and apoptosis. In murine brains, 
it was reported that p53 deficiency played a central role in driving gliomagenesis 
(Wang et al., 2009). Neuronal injury, especially damage mediated by excitotoxicity, is 
associated with increased production of reactive oxygen species and accumulation of 
single-strand DNA breaks.  Cell culture studies have established strong correlations 
between p53 expression and excitotoxic neuronal death induced by glutamate and 
NMDA (Culmsee and Mattson, 2005). The absence of p53 has been shown to protect 
neurons in-vivo from a wide variety of toxic insults including focal ischemia 
(Crumrine et al., 1994). The signaling pathways activated by Akt phosphorylation 
have been summarized in Figure 1.6. 
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Figure 1.6: Akt – Master regulator for cell fate.  
Once activated Akt pathway is involved in mediating various biological responses which 
promote cell survival after injury. (Adapted from Cell Signaling Technology, Inc., 
http://www.cellsignal.com). 
 
1.9. Role of FSAP in vasculature 
FSAP is predominantly produced as an inactivate zymogen molecule of 78 
kDa that can be converted in its active two-chain form consisting of a 50 kDa heavy 
and a 28 kDa light chain connected by a disulfide bond in the liver. FSAP consists of 
560 amino acids including a 23 amino acid pro-peptide at the amino terminal part of 
the molecule. FSAP consists of three epidermal growth factor (EGF) domains, a 
kringle domain, a serine protease domain at its C terminus (Figure 1.7) (Choi-Miura 
et al., 1996). The circulating plasma concentration of FSAP is 12 µg/ml (180nM) and 
it can be activated by factors released from apoptotic or dead cells, e.g. histones and 
nucleosomes (Kanse et al., 2008). Once activated, FSAP is capable of activating other 
FSAP molecules in an autocatalytic fashion. Single-chain FSAP (scFSAP) in purified 
systems has been reported to be susceptible to auto-proteolysis. FSAP can also be 
auto-activated upon binding to negatively charged polyanions, such as hyaluronic 
acid, heparin, and nucleic acids. Apart from FVII, several other substrates for FSAP 
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have been identified including fibrinogen, fibronectin, high molecular weight 
kininogen (HMWK), single-chain urokinase -type plasminogen activator (scu-PA), 
FV, FVIII, and more recently the tissue factor pathway inhibitor (TFPI) (Muhl et al., 
2009; Kanse et al., 2012). After in-vivo activation complex formation of FSAP has 
been observed especially with α2-plasmin inhibitor and C1 inhibitor (Stephan et al., 
2011) . In in-vitro experiments, FSAP has been shown to promote fibrinolysis through 
activation of sc u-PA, and sc u-PA, in turn, can activate FSAP at a high enzyme to 
substrate ratio. FSAP is also a potent inhibitor of platelet-derived growth factor-BB 
(PDGF-BB), which has an important role in vascular smooth muscle cell proliferation 
and migration (Muhl et al., 2007).  
 
1.10. FSAP Single Nucleotide Polymorphisms (SNPs) and Stroke 
FSAP is encoded by the hyaluronic acid binding protein 2 (HABP2) gene. 
There are two prominent single nucleotide polymorphisms (SNP) which exist in the 
FSAP encoding gene, G534E (Marburg I, MI) and E393Q (Marburg II, MII), that 
each result in an exchange of a single amino acid in the protease domain which leads 
to loss of enzymatic activity (Figure 1.7) (Kannemeier et al., 2001; Romisch et al., 
2001). About 6–9% of the Caucasian population is heterozygous carrier of each SNP 
(Romisch et al., 2001).  Two other SNPs also lead to an exchange of a single amino-
acid, but these SNPs are located in the heavy chain, in the EGF domains. These 
exchanges are S56T and I90V, respectively, their location in the heavy chain suggests 
no consequences for proteolytic activity. 
In the analysis of the Bruneck Study the homozygous allele of the MI-
polymorphism was shown to be strongly linked to late complications of carotid 
stenosis (Willeit et al., 2003). In another clinical trial, the FSAP-MI-SNP was also 
determined as a risk factor for cardiovascular disease in general. In one study, it was 
shown that FSAP-MI was associated with venous thromboembolism while others 
indicated no correlation (Kanse et al., 2008). In the PROSPER study, the Marburg I 
polymorphism was associated with an increased risk of clinical stroke (HR: 1.60, 95% 
CI: 1.13–2.28) and all-cause mortality (HR: 1.33, 95% CI: 1.04–1.71) (Trompet et al., 
2011).  
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Figure 1.7: Structure of FSAP.  
Inactive single-chain conformation (top) and active two chain conformation (bottom) of 
FSAP with EGF kringle and serine protease domains indicated. The cleavage site is 
highlighted by the blue arrow, cleavage occurs at R▼I314. The arrows highlight locations of 
SNP, in either heavy-chain or light-chain Adapted from (Kanse et al., 2008).  
 
We recently investigated whether FSAP antigen and activity levels are 
associated with ischemic stroke and/or etiologic subtypes of ischemic stroke (Hanson 
et al., 2012). To assess the potential association between FSAP and ischemic stroke, 
plasma FSAP antigen and activity were measured in 600 consecutive IS patients and 
600 population-based controls from the case-control study the Sahlgrenska Academy 
Study on Ischemic Stroke (SAHLSIS). Both the FSAP antigen and activity levels 
were significantly increased in patients with IS, both in the acute phase and at the 3-
month follow-up, as compared to controls (Hanson et al., 2012). In patients, FSAP 
activity was significantly higher in the acute phase compared with the follow-up 
measurement (mean 1274 mU/mL compared to 1214 mU/mL, P<0.001). It is possible 
that the increased acute phase FSAP activity is, to some extent, a result of tissue 
injury after stroke which leads to the release of apoptotic or dead cells. By contrast, 
there was no difference between the acute phase and follow-up FSAP antigen levels. 
Both FSAP antigen and activity were significantly lower in carriers of the A allele 
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(n=43) of the MI-SNP, compared to homozygotes for the wild-type G allele (n=546), 
(geometric mean 10.3 vs. 12.3 µg/mL, and mean activity 668 vs.1141 mU/mL, 
respectively, P<0.001 for both) (Hanson et al., 2012). However, the mechanisms by 
which FSAP might influence the pathophysiology of stroke remain elusive.  
It is possible that FSAP through prothrombotic mechanisms (by inhibition of 
TFPI) might contribute to ischemic stroke (Kanse et al., 2012). However, there is no 
direct evidence linking TFPI levels and ischemic stroke occurrence. Recently we 
demonstrated a protective role for FSAP in liver fibrosis. In this study, bile duct 
ligation was used as a method for inducing liver fibrosis in mice (Borkham-
Kamphorst et al., 2013). It is known that bile duct ligation induces hypoxia 
(Rosmorduc et al., 1999) and inflammation (Iredale, 2007). This role of FSAP in 
dampening of inflammation might also influence stroke outcome. Many studies have 
indicated that FSAP is also likely to have effects outside the hemostasis system 
analogous to plasminogen with which it shares high homology. It was shown that 
FSAP could influence endothelial permeability via Protease-activated receptor-1 
(Mambetsariev et al., 2010).  Activated protein C (APC) is similar to FSAP in that it 
also activates PAR-1 and recent studies have shown that APC exerts direct anti-
apoptotic effects in neurons (Guo et al., 2004; Mosnier et al., 2007; Griffin et al., 
2012). Protease-activated receptors (PARs) (PAR1-4) a family of G protein-coupled 
receptors (GPCRs), are widely expressed in the central nervous system (CNS), 
including neurons, microglial cells, astrocytes, and oligodendrocytes. Increasing 
evidence over the recent years has demonstrated that PAR-1, the main subtype of 
PARs, plays an important role in brain (Rohatgi et al., 2004).  It was also reported that 
PAR-1 activation by thrombin treatment remarkably increases levels of glutathione 
peroxidase in human astrocytes, which protects neurons from the toxicity of thrombin 
at high concentration (Ishida et al., 2006).  Thus, interactions of FSAP with PAR-1 
receptor on astrocytes and neurons could be a possible mechanism by which FSAP 
may influence stroke pathophysiology. 
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2. Specific Aims 
FSAP encoding gene has been associated with increased stroke mortality and 
morbidity in human genetic studies. However, to date no information is available as 
to what the function of FSAP may be in the context of stroke. Normally, poor outcome 
in stroke is associated with blood brain barrier dysfunction and secondary 
microinfarctions or the absence of a neuroprotective agent which finally culminates 
into edema formation and mortality. We have analyzed the pathophysiological role of 
FSAP in stroke using in-vitro cell culture based models and in-vivo using FSAP -/- 
mice. Thus, the specific aims of this thesis were: 
 
1. Determine if FSAP can cross through the blood brain barrier by in-vitro 
model and if it influences permeability under conditions mimicking stroke; 
identification of this will be helpful to understand if FSAP can reach the 
neurons and astrocytes and if it regulates BBB permeability; 
2. To investigate the effect of FSAP on cell death/ apoptosis of primary cortical 
astrocytes under hypoxia reperfusion injury conditions;  
3. Elucidate the effect of FSAP on cell death/ apoptosis of primary cortical 
neurons under excitotoxicity and ischemia reperfusion injury;  
4. Examine the role of FSAP in-vivo using murine thromboembolic stroke model 
using FSAP -/- mice. 
. 
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3. Materials & Methods 
 
3.1. Human plasma FSAP. 
The preparation of FSAP and Phe-Pro-Argchloromethylketone (PPACK)-
inactivated FSAP from human plasma has been described before (Roedel et al., 2013).  
 
3.2. Primary Cell culture 
3.2.1 Neurons 
Cortical neurons were prepared from fetal mice (E15-E16). Dissociated 
cortical cells were resuspended in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 5% (vol/vol) fetal bovine serum, 5% (vol/vol) horse serum, and 1 
mM glutamine, and plated in 24-well dishes previously coated with poly-D-lysine and 
laminin. After 3 days, the cells were exposed to 10 uM Ara-C to inhibit glial 
proliferation. Cultures were used after 14 DIV for excitotoxicity and hypoxia assays. 
Cultures from 3 different isolations were stained with neuronal nuclei antibody (Anti 
NeuN, MAB377, Millipore, MA, USA) and 95% of the cells were identifiable as 
neurons. 
 
3.2.2 Astrocytes 
Primary astrocytes were prepared as described elsewhere (Gorina et al., 2009). 
Following isolation of cortices and removal of the meninges, dissociated cells were 
suspended in Dulbecco's Modified Eagle's Media (DMEM) F12 containing 20% fetal 
bovine serum (FBS) and 0.25% gentamycin, and plated on 10 mm dish pre-coated 
with 0.1 mg/ml poly-L-lysine. Cultures were maintained for 14 days to generate a 
confluent glial culture. Prior to trypsinization, contaminating microglial cells were 
separated by mechanical agitation and removed by subsequent washing in Hank's 
Balanced Salt Solution (HBSS). Astrocytic monolayers were then dislodged from 
flasks by trypsinization (0.25% trypsin in HBSS and 1 mM EDTA). Cells were 
seeded in either 24 well plates (1 × 105 cells/well) or 75 cm2 flasks (5 × 105 cells/flask) 
and grown for 14-16 days until confluent prior to stimulation. Cultures were routinely 
more than 95% pure astrocytes when assessed by glial fibrillary acidic protein 
(GFAP) immunostaining. 
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3.2.3 Primary mouse brain microvascular endothelial cells (pMBMECs)  
pMBMECs were isolated from 4- to 6-week old C57BL/6 mice, cultured in 
DMEM, 20% (vol/ vol) FCS, 1 mmol/L sodium pyruvate, 1% (vol/ vol) minimal 
essential medium nonessential amino acids, 50 ug/mL gentamycin, and 1 ng/mL basic 
fibroblast growth factor (bFGF) as exactly as described before (Gorina et al., 2013). 
During the first 48h, the media was supplemented with the translator inhibitor 
puromycin at 4µg/mL to obtain higher pMBMEC purity. Forty-eight hours after 
seeding, pMBCEC monolayers growing on the inserts were set in the 24-well culture 
plates containing the astrocytes. The medium was changed and the media used for 
luminal and the abluminal compartments (co-culture medium) consisted of DMEM 
with 10% FBS (PAA), 2X NEAA, 2X NaPyr, gentamycin (Gibco-BRL) with bFGF. 
Once the cells were in co-culture, the medium was renewed every two days. Under 
these conditions, pMBCECs migrated from digested microvessels reached confluence 
about 4 days after plating. Experiments were carried out 4-5 days after setting up the 
co-culture. 
 
3.3. Permeability assay 
Permeability assays were performed in triplicate as published previously 
(Coisne et al., 2005). pMBMECs were grown to confluence on matrigel coated filter 
inserts, washed with wash buffer (HBSS, 10% FCS, 25 mmol/L Hepes pH 7.2 to 7.5) 
and permeability to AlexaFluor-680-dextran (3 kDa, 10 µg/mL, LuBioScience, 
Luzern, Switzerland) was measured in the presence of the assay medium (DMEM, 5% 
FCS, 4 mmol/L -glutamine, 25 mmol/L Hepes pH 7.2 to 7.5). Endothelial 
permeability was specifically measured at 2 and 24 hours of reoxygenation after 
OGD. Diffused AlexaFluor-680-dextran was quantified using the Odyssey Infrared 
Imaging System (LI-COR, Bad Homburg, Germany).  To measure diffusion of FSAP 
across the BBB, FSAP was added to the luminal side. Medium from the abluminal 
side of the insert was removed at the indicated times and analysed by ELISA.  
 
3.4. FSAP ELISA 
Microtiter plates were coated with a rabbit polyclonal anti-FSAP Ab (5 µg/ml) 
and blocked with 3% (wt/vol) BSA, 0.1% (wt/vol) Tween 20 in TBS. Cell 
supernatants were incubated for 1 hour at RT. After extensive washing, anti-FSAP 
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mAb 570 (2 ug/ml) was added and incubated (1 hour, RT). It was followed by 
incubation of peroxidase-coupled mouse Ab. The resolution of the ELISA was done 
using 3,3‘,5,5‘-Tetramethylbenzidin (TMB-Substrate-Kit, Pierce, Rockford, Il, USA) 
and the optical density was measured at 405 nm using microplate reader EL808 
(Biotek Instruments, Winooski, OR, USA). Using a standard curve with Standard 
Human Plasma from Siemens Diagnostics (Marburg, Germany), the concentration of 
FSAP across the BBB was calculated. 
 
3.5. NMDA mediated Excitotoxicity  
Excitotoxicity was induced at 37°C by a 24 hour exposure to 12.5 uM NMDA 
in DMEM supplemented with glycine (10 uM). Neuronal death was quantified by 
measurement of lactate dehydrogenase (LDH) release by damaged cells into the 
bathing medium. The LDH level corresponding to complete neuronal death was 
determined in parallel cultures exposed to 200 uM NMDA for 24 hours in DMEM 
supplemented with glycine. Background LDH levels were determined in parallel 
cultures subjected to sham wash and subtracted from experimental values to yield the 
signal specific to experimentally induced injury. 
 
3.6. Oxygen-glucose deprivation injury in neurons and astrocytes 
Primary astrocytes were subjected to oxygen glucose deprivation (OGD) by 
adding OGD medium containing glucose- and serum-free DMEM (OGD medium-1) 
and placed for 6 h under 1%O2, 5% CO2, 37 °C in a CO2 incubator (Innova CO-48; 
New Brunswick 210 Scientific, USA) for 6h followed by a period of 24 h under 20% 
O2, 5%, CO2, 37 °C (reoxygenation) in fresh medium containing DMEM with glucose 
supplemented with 1X NEAA, 1X NaPyr and reoxygenation medium - 1. 
Primary neurons were incubated in OGD medium-1 for 2 h at 1%O2, 5% CO2, 
37 °C in a CO2 incubator followed by 24 h (reoxygenation) under 20% O2, 5%, CO2, 
37 °C (reoxygenation) in fresh reoxygenation medium – 1. 
 
3.7. Oxygen-glucose deprivation injury in BBB 
For the BBB experiments, co-cultures were subjected to OGD by adding a 
OGD medium and placed for 6 h in an anoxic atmosphere using GasPack EZ bags 
(Becton Dickinson, Sparks, MD, USA). The cells were washed in OGD medium-2 
containing glucose and serum free DMEM, Hepes 25nM and gentamycin After the 
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OGD period media was changed for fresh reoxygenation medium-2 containing 
DMEM with glucose supplemented with 1X NEAA, 1X NaPyr, 25mM Hepes and 
gentamicin. For normoxic controls, cells were exposed to DMEM containing glucose 
with Hepes 25mM and gentamicin during the OGD period and after that, media was 
changed for reoxygenation medium. 
 
3.8. Transient H2O2 injury 
Cultured cells were incubated at 37°C with fresh serum-free culture medium 
in the absence or presence of H2O2 (250 µM) for 3 h. After the H2O2 treatment, 
medium was changed and different inhibitors were added for 24 h.  
 
3.9. Total RNA isolation and real-time PCR 
Total RNA was extracted using the Total RNA Miniprep kit (Sigma Aldrich 
(Taufkirchen, Germany). Reverse transcription was performed using the High 
Capacity cDNA reverse transcription kit (Applied Biosystems, Germany). 
Quantitative real-time PCR was performed using the SensiMix SYBR kit (Bioline 
GmbH, Luckenwalde, Germany), and fluorescence of amplified DNA was detected 
by the Step One Plus real-time PCR system (Applied Biosystems, Germany). The 
temperature program of DNA amplification was as follows: cDNA denaturation at 95 
°C for 15 s, primer hybridization at 60 °C for 30 s, and elongation at 72 °C for 30 s. 
The amplification plot was monitored over 40 cycles, and continuous fluorescence 
measurement indicated mRNA expression of analyzed genes. Fluorescent threshold 
cycles (Ct) were set and normalized against Ct of housekeeping gene GAPDH (∆Ct). 
Subsequently, expression of the target gene was controlled with the reference probe, 
and target Ct was calculated as 2 −∆∆Ct.  Data is thus expressed as fold change 
compared to unstimulated cells. 
 
3.10. Caspase 3/7 activity assay 
Caspase-3 is activated in the apoptotic cell both by extrinsic (death ligand) and 
intrinsic (mitochondrial) pathways. The caspase-3 zymogen has virtually no activity 
until it is cleaved by an initiator caspase after apoptotic signaling events have 
occurred especially after ischemic insult. Hence, Caspases-3/7 activities were 
measured using Caspase 3/7 homogeneous according to manufacturer’s protocol 
(Promega, USA). In brief, at the end of treatment, neurons and astrocytes were 
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washed with PBS and 300 µL of caspase- 3/7 reagent was added to each well and the 
cells were scraped and collected in a microfuge tube in dark. The cell lysate was 
incubated in dark for 30 min and the resultant fluorescence was measured. The results 
are expressed as fold change in Caspase 3/7 activity from control. 
 
3.11. Viability assays 
Cell death was quantified by measurement of the activity of lactate 
dehydrogenase (LDH) released from damaged cells into the supernatant with a kit 
(Roche Diagnostics, Mannheim, Germany). In addition, cytotoxicity was also 
quantified by measurement of the reduction of 3-(4, 5-dimethylthiazol-2-yl) 2, 5-
diphenyl-tetrazolium bromide (MTT) (Sigma Aldrich, Taufkirchen, Germany) to 
produce a dark blue formazan product. This assay assesses the integrity of 
mitochondrial function. MTT was added to each culture well at a final concentration 
of 0.5% MTT solution (wt/vol). After incubation for 4 hours at room temperature, the 
medium was moved, and cells were dissolved in 150 µL DMSO for 1 hour. The 
formation of formazan was measured by reading absorbance at a wavelength of 570 
nm with a reference setting of 630 nm on a microplate reader EL808 (Biotek 
Instruments, Winooski, OR, USA).   
 
3.12. DNA fragmentation by terminal deoxynucleotidyl transferase-mediated dUTP 
nick end labeling (TUNEL) assay 
TUNEL staining was performed with the Fluorescein In Situ Cell Death Detection Kit 
(Roche, Mannheim, Germany) according to the manufacturer's instructions. Cells 
were fixed with 4% (vol/ vol) formaldehyde in PBS pH 7.4 for 30 minutes and 
permeabilized by 0.5% (wt/ vol) Triton X-100 in TBS. DNA strand breaks were 
labeled with digoxigenin-deoxy-UTP using terminal deoxynucleotidyl transferase 
(TdT, 0.18 U/µL) using manufacturer’s protocol. The incorporation of nucleotides 
into the 3′-OH end of damaged DNA was detected with an anti-digoxigenin-
fluorescein antibody. Slides were mounted with mounting medium for fluorescence 
containing DAPI for DNA staining and visualized in a fluorescence microscope. 
Negative control slides were incubated in absence of TdT. 
 
 
 
Chapter 3. Materials & Methods  
_____________________________________________________________________ 
 - 23 - 
3.13. Preparation of Cell Extracts and Western Blotting 
Cell extracts were prepared in lysis buffer containing 200 mM HEPES at pH 
7.4, 100 mM NaCl, 100 mM NaF, 1 mM Na3VO4, 5 mM EDTA, 1% Triton-X-100 
and a protease inhibitor cocktail (COMPLETE™, Roche, Basel, Switzerland). Cells 
were left for 20 minutes on ice in lysis buffer. Subsequently, we obtained the cell 
extract and we added Laemmli sample buffer. Samples were boiled for 10 min and 
resolved by Tris/Glycine SDS-Polyacrylamide gel electrophoresis. Proteins were 
transferred onto PVDF membrane (GE Healthcare, Frankfurt, Germany). The 
membranes were incubated overnight with primary antibodies diluted in 5% nonfat 
milk (wt/ vol) or 5% BSA (wt/ vol) in TBS, and then washed and incubated with a 
HRP-secondary antibody for 1 hr. The relative abundance of proteins was determined 
by scanning densitometry and expressed relative to control groups and reference 
proteins that were arbitrarily assigned as 1. 
 
3.14. Immunocytochemistry  
8-well chamber slides (Nunc, Wiesbaden, Germany) containing cortical 
astrocytes or neurons were fixed in 4% buffered PFA in phosphate-buffered saline 
(PBS; Sigma-Aldrich). Fixed cells were permeabilized and blocked (1% BSA and 
0.1% Triton-X in PBS) at room temperature for 1 h before overnight incubation at 
4°C with Glial fibrillary acidic protein (GFAP) or neuron-specific nuclear protein 
(NeuN/ Neuronal Nuclei) antibody. Following primary incubation, the slides were 
incubated in the appropriate Alexa Fluor-conjugated secondary antibodies 
(Invitrogen) for 1 h at room temperature. Following secondary incubation, slides were 
sealed with mounting solution (Sigma-Aldrich) on cover-slips.  
Confluent pMBMEC grown on trans-well inserts were washed in Tris-
buffered saline (TBS) and exposed to test substances as described above for 
permeability assays (Gorina et al., 2013). Cells were fixed with 1% (wt/vol) 
paraformaldehyde in phosphate-buffered saline for 10 minutes at room temperature 
and blocked with blocking buffer (5% skimmed milk (wt/vol), 0.3% Triton X-100 
(vol/vol) and 0.04% (wt/vol) NaN3 in TBS) for 30 min at RT. The inserts were then 
incubated with rabbit anti-mouse ZO-1 (617300, Invitrogen, 1:100) 1h. After 
washing, cells were incubated for 60 min with Alexa Fluor 488-conjugated goat anti-
rabbit IgG (Molecular Probes, Eugene, OR, USA, 1:1000), and mounted with 
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Mowiol. Pictures were taken using a fluorescence microscope (Leica DMRB, Leica 
Microsystems, Wetzlar, Germany). 
 
3.15 Animal housing conditions and ethical considerations  
Male (10–14 weeks) C57/ BL6 (Janvier, France) and FSAP-/- mice, 
backcrossed atleast 10 generations, were housed in a temperature-controlled room on 
a 12 hour light/12-hour dark cycle with food and water ad libitum. Experiments were 
performed at Cyceron, Caen France, in collaboration with Prof. Denis Vivien and Dr. 
Cyrille Orset. Experiments were in accordance with French ethical laws (act no. 87–
848; Ministe`re de l’Agriculture et de la Foreˆt) and European Communities Council 
Directives of November 24, 1986 (86/609/EEC) guidelines for the care and use of 
laboratory animals. 
 
3.16. Induction of Ischemic stroke and Physiological Monitoring  
Mice were randomized, and experiments were performed as described before 
(Orset et al., 2007) in a blinded fashion. Animals were deeply anesthetized with 
isoflurane 5% and, thereafter, maintained with 2.5% isoflurane in a 70%/30% mixture 
of NO2/O2. MCA occlusion was induced by thrombin injection, as described 
elsewhere. Briefly, the skin between the right eye and the right ear was incised and 
the temporal muscle was retracted. To expose the MCA, a small craniotomy was 
performed and the dura mater was excised. A micropipette was introduced into the 
lumen of the MCA and 2 µL (1.5 U) of purified murine alpha-thrombin 
(Haematologic Technologies, Vermont, USA) was injected to induce the formation of 
a clot. Ten minutes after injection the clot had stabilized and the micropipette was 
removed. After surgery the incision wound was sutured. Rectal temperature was 
maintained at 37 ± 0.5°C throughout the surgical procedure using a feedback-
regulated heating system. 
 
3.17. Monitoring of Cerebral Blood Velocity by Laser Doppler Flowmetry 
Cerebral blood velocity was determined by laser Doppler flowmetry using a 
fiberoptic probe (Oxford Optronix) glued to the skull in the MCA territory. Cerebral 
blood velocity was measured before the injection of alpha-thrombin (100% baseline) 
and throughout the duration of the experiment (60 minutes). 
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3.18. Stroke assessment by magnetic resonance imaging 
Magnetic resonance imaging (MRI) was performed 24h after stroke on a 
dedicated 7T MR small animal imaging system (ClinScan, Bruker, Ettlingen, 
Germany). The animals were anesthetized with 1.5-2% isofluran and positioned into 
the magnet with a laser-controlled system for the animal cradles. Respiratory 
frequency and body temperature were monitored throughout the experiment and the 
latter was maintained with a water heating pad. The image protocol comprised T2-
weighted imaging and diffusion-weighted imaging (DWI). To calculate infarct 
volume as the percentage of hemisphere that is infarcted (% of infarcted hemisphere), 
we estimated the volume of the contralateral hemisphere (CH) and that of the non-
lesioned ipsilateral hemisphere (NLH). The percentage of infarcted hemisphere was 
then calculated using the formula = (CH-NLH/CH) X 100. Volume was normalized 
by edema index, which is the ratio between the volume of the contralateral and 
ipsilateral hemisphere. 
 
3.19. Angiography  
Magnetic resonance angiographies (MRA) were performed using a 2D-TOF 
sequence (TE/TR 10/50 ms). Analyses of the MCA MRA were performed blinded to 
the experimental data using the following score: 2: normal appearance, 1: partial 
occlusion and 0: complete occlusion of the MCA. 
 
3.20. Laser Speckle Flowmetry (LSF)  
Laser speckle perfusion imaging of the brain was performed using 
moorFLPI2, Full-Field Laser Perfusion Imager (Moor Instruments, Devon, UK) 
according to the manufacturer’s instructions and as described previously (Manwani et 
al., 2013). Briefly, a midline scalp incision was made, the skull was exposed and the 
charge coupled device camera of LSF was installed 30 cm above the skull using an 
articulating arm. Complete hemispheres were used to evaluate the relative cerebral 
perfusion. The imaging was set up at a display rate of 25 Hz, time constant of 1 
second, and a camera exposure time of 4 milliseconds.  
 
3.21. Neuroscore  
Neurological evaluation was performed 24 hours after induction of ischemia 
and scored on a 6-point scale. 0 = no apparent deficit, 1 = contralateral forelimb 
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flexion; 2 = decreased grip of contralateral forelimb grip while tail pulled; 3 = 
spontaneous movement in all directions, contralateral circling only if pulled by tail; 4 
= spontaneous contralateral circling; 5 = no movement.  
 
3.22. Mouse Brain Extracts for SDS page 
Animals were euthanized 24 hours post stroke induction and brains were 
directly prepared in cold PBS. Hemispheres were separately homogenised 
mechanically in homogenisation buffer (140 mM NaCl; 20 mM Tris-HCl pH 7,6; 5 
mM EDTA; 16 complete protease inhibitors) and extracts additionally sonicated for 
30 s. Resulting extracts were centrifuged (6000 rpm) for 10 min at 40C. Supernatants 
were further centrifuged (14000 rpm) for 10 min at 40C. 
 
3.23. Mouse Plasma FSAP activity 
Total FSAP activity was measured by an immunocapture activity test using 
the buffers and procedures as described, with minor modifications. Microtiter plates 
were coated with 10µg/ml anti-FSAP mouse polyclonal antibody (MENEW) in 
coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6), followed by blocking with 
standard buffer (20 mM Na-citrate, 150 mM NaCl, 100mM Arginin, pH 6.0) 
containing 3% BSA (wt/vol). Plasma probes were diluted (1:100) in a standard buffer 
(see above) containing 0.1% Tween 80 (wt/vol), 1% BSA (wt/vol) and 100U/ml 
unfractionated heparin (Liquemin, Roche, Grenzach, Germany) and applied on the 
plate, incubated for 1 hour at room temperature (RT) and washed three times. 
Recombinant single-chain uPA (10µg/ml Saruplase, Grünenthal, Stolberg, Germany 
in TBS with 0.1% Tween 80 /wt/vol), 2 mM CaCl2, pH 7.2) was added and incubated 
for 5 min followed by chromogenic substrate S-2444 (2 mM) (Haemochrome, Essen, 
Germany) and further incubated (37°C). Absorbance at 405 nm was recorded every 
minute with microplate reader EL808 (Biotek Instruments, Winooski, OR, USA) over 
1 hour (37°C). The maximal velocity (substrate turnover with time) over 8 min was 
determined and this was invariably always the initial reaction velocity. For the assay, 
calibration curves were established through a dilution series of Standard Human 
Plasma (SHP, Siemens Diagnostics, Marburg, Germany). SHP served as reference for 
the measured FSAP activity, which was defined as 1 plasma equivalent unit (1000 
mU/ml).  
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3.24. Statistics 
Generally each in-vitro experiment was performed in duplicates on at least 3 
different isolations of cells from independent cell culture preparations. Results are 
presented as means ± S.D. Between-group comparisons were performed with one-way 
ANOVA and Tukey post-test. One-way ANOVA and post hoc Tukey's multiple 
comparison test. *P<0.05 **P<0.01 and ***P< 0.001 indicate statistically significant 
differences. Number of animals in each experiment and the statistical significance are 
presented in figure legends. 
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4. Results 
4.1. FSAP can cross the BBB and protects the endothelial barrier integrity upon 
oxygen glucose deprivation (OGD) and reoxygenation-injury 
To determine the effect of FSAP on the BBB permeability after an ischemic 
insult, we used primary mouse brain microvascular endothelial cells (pMBMECs) in 
co-culture with primary mouse astrocytes as an in-vitro model of the BBB (Enzmann 
et al., 2013). We observed that addition of FSAP (100nM) on the luminal endothelial 
side decreased the OGD/reoxygenation-induced permeability of the BBB as shown by 
a reduction in the permeability coefficient for 3KDa labeled-dextran (Figure 4.1 A). 
FSAP also reduced the release of LDH after OGD followed by 24 h of reoxygenation 
suggesting that FSAP could protect the endothelial cells against oxidative stress-
related cell death (Figure 4.1 B). FSAP was able to cross BBB under normoxic 
conditions and increased passage was observed after OGD/ reoxygenation (Figure 4.1 
C,D). Thus, FSAP decreased the permeability of the in-vitro BBB under conditions 
that mimick stroke followed by reperfusion. Surprisingly, although FSAP decreased 
permeability, the passage of FSAP itself was higher under conditions of 
OGD/reoxygenation.  
We then analyzed Zonula occludens-1 (ZO-1) expression by staining as it is a 
junctional protein that regulates endothelial permeability (Fischer et al., 2002; 
Zehendner et al., 2011). We observed that its localization in endothelial junctions was 
altered after OGD/reoxygenation, but in the presence of FSAP the junctional 
localization of ZO-1 was preserved (Figure 4.1 E). Inhibition of the FSAP proteolytic 
activity with the protease inhibitor Aprotinin completely blocked the protective effect 
of FSAP after OGD/reoxygenation (Figure 4.1).  ZO-1 expression is a surrogate 
marker of endothelial cell permeability and its organized junctional distribution is 
disturbed by OGD/ reoxygenation. FSAP prevented this disruption of ZO-1 
expression, suggesting a protective effect on barrier function. 
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Figure 4.1: FSAP treatment protects the blood-brain barrier integrity during 
OGD/reoxygenation injury in-vitro. 
A. Effect of treatment with FSAP (100 nM) after normoxia (white bars) or 
OGD/reoxygenation (OGD) (black bars) on pMBMEC permeability.  Aprotinin (APO) (10 
µg/ml) and tPA (20 µg/ml) were used to demonstrate the specificity of the FSAP protective 
effect. B. FSAP protected pMBMEC from OGD/reoxygenation-induced cell death as 
quantified by LDH release. C-D. FSAP was added on the BBB endothelial luminal side at the 
beginning of the reoxygenation phase and its concentration was measured by ELISA in the 
abluminal side after 2 hours (C) or 24 hours of reoxygenation (D).  E. Immunofluorescence 
staining for ZO-1 in pMBMECs grown in co-culture with astrocytes. ZO-1 distribution under 
normoxic conditions (1), after OGD/reoxygenation (2), in the presence of FSAP after 
OGD/reoxygenation (3) and FSAP in the presence of Aprotinin after OGD/reoxygenation (4). 
Mean ± SD, n ≥ 3 independent cultures in duplicates. One-way ANOVA and post hoc Tukey's 
multiple comparison test. *P<0.05 indicates statistically significant differences. 
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4.2. FSAP decreases cell death after OGD/reoxygenation in astrocytes 
Astrocytes are known to play a critical role in the progression of ischemic 
stroke. After injury, astrocytes form a glial scar which helps to isolate the necrotic 
tissue from the rest. Multiple studies have shown the beneficial effects of astrocytic 
protection in improving the stroke outcome as they provide support to neurons. Hence 
we decided to see if FSAP could induce a protective effect on astrocytes exposed to 
ischemic insult. Cortical astrocytes in culture were exposed to OGD (6 hours) 
followed by 24 hours of reoxygenation with glucose. This has been used as a model to 
mimick the clinical situation wherein ischemia is followed by reperfusion that leads to 
cell death.  
Treatment with FSAP prevented cell death in hypoxic astrocytes as measured 
by LDH release (Figure 4.2A) and mitochondrial-function assay (Figure 4.2B). We 
then evaluated the levels of apoptosis in the presence of FSAP by measuring the 
number of TUNEL-positive apoptotic cells and the enzymatic activity of caspase-3/7. 
OGD/reoxygenation induced activation of caspase-3/7 (Figure 4.2C) and the number 
of cells undergoing apoptosis (Figure 4.2D, 4.2E) was reduced in the presence of 
FSAP.  Inhibition of FSAP activity by the serine protease inhibitors, PPACK and 
Aprotinin (Figure 4.2), inhibited the anti-apoptotic effect of FSAP. As in the case of 
pMBMECs, we observed that FSAP inhibited cell death and apoptosis in astrocytes. 
These effects also required the proteolytic activity of FSAP.  
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Figure 4.2: FSAP protects astrocytes from OGD/reoxygenation injury.  
A-B. Effect of FSAP or PPACK-FSAP (100 nM) in astrocytes after 24 h of 
OGD/reoxygenation (OGD)  (black bars) on cell survival was quantified by LDH (A) and 
MTT reduction assay (B). White bars represent normoxic untreated controls. C.  Caspase-3 
activity astrocytes after 12 h of reoxygenation in the presence or absence of FSAP and/or 
Aprotinin (APO) (10 µg/ml) and quantified relative to untreated control. D. The number of 
apoptotic TUNEL-positive cells were quantified as described in the Methods. Fold change 
was calculated relative to untreated control. E. Representative fluorescent-TUNEL 
(green)/dapi (blue) staining in mouse cortical astrocytes 24 h after OGD treatment in the 
presence or absence of FSAP and/ or Aprotinin.  Mean ± SD, n ≥ 3 independent cultures in 
duplicates. One-way ANOVA and post hoc Tukey's multiple comparison test. *P<0.05 
**P<0.01 and ***P< 0.001 indicate statistically significant differences. 
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4.3. Activation of PI3K-Akt signaling pathway by FSAP protects astrocytes from 
OGD/reoxygenation-mediated cell death 
Cell death was prevented by FSAP as measured by LDH release (Figure 
4.3.1A) and mitochondrial function test (Figure 4.3.1B) in a concentration-dependent 
manner (12.5 nM – 100 nM), with maximal antiapoptotic effect at 100 nM. Since the 
PI3K-Akt pathway has been implicated to be the most important pathway in 
regulating the apoptotic response to hypoxia (Li et al., 2013), we measured if FSAP 
was able to induce phosphorylation of Akt on Ser473. We observed that FSAP was 
able to activate the PI3K-Akt signaling pathway in a concentration-dependent manner 
(Figure 4.3.1C). Inactivation of FSAP with either PPACK or Aprotinin removed the 
protective effects induced by FSAP mediated Akt phosphorylation (Figure 4.3.2.A,B).  
To further validate our observations that FSAP induced Akt phosphorylation, 
LY294002 (10 µM) or Wortmannin (0.5 µM), inhibitors of PI3K-dependent Akt 
signaling, were added to the cultures 1 h before OGD exposure. LY294002 and 
Wortmannin both blocked FSAP-mediated phosphorylation of Akt as well as FSAP-
mediated cell protection (Figure 4.3.1D & 4.3.1E) indicating the requirement of 
PI3K-dependent Akt signaling pathway. Only active FSAP was able to induce potent 
Akt phosphorylation at all measured time points (Figure 4.3.2.A,B). This data 
suggests that the activation of PI3K-Akt by only active FSAP is ultimately 
responsible for the antiapoptotic effect in cultured astrocytes challenged with OGD. 
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Figure 4.3.1: FSAP reduces cell death in OGD/reoxygenation astrocytes via the 
PI3K-AKT pathway.  
A-B. LDH release (A) and mitochondrial function (B) were quantified in astrocytes subjected 
to OGD and treated with FSAP (0-100 nM) during the reoxygenation phase for 24h. Values 
relative to normoxic cells (100%). C. Western blots for pAkt (Ser473) and total Akt in whole-
cell extracts. Intensity of pAkt signal was measured by scanning densitometry and normalized 
to total Akt at 24 hours. Fold change was calculated relative to untreated control. D-E. 
Survival of mouse cortical astrocytes 24 h after OGD/reoxygenation in the presence or 
absence of FSAP (100 nM), LY294002 (10 µM) or Wortmannin (0.5 µM) was measured 
using LDH release assay (D) and MTT reduction assay (E) . LY294002 (LY) and 
Wortmannin (WO) were added to the culture supernatant 1 h before OGD (OGD, black bars).  
Mean ± SD, n ≥ 3 independent cultures in duplicates. One-way ANOVA and post hoc Tukey's 
multiple comparison test. *P<0.05 **P<0.01 and ***P< 0.001 indicate a statistically 
significant differences. 
 
Chapter 4. Results 
_____________________________________________________________________ 
 - 34 - 
Figure 4.3.2: FSAP activates Akt phosphorylation in normoxic and hypoxic 
astrocytes.  
(A). Representative western blot of the effect of FSAP or PPACK- FSAP (100nM) in the 
absence or presence of Aprotinin (APO) (10 µg/ml) on Akt phosphorylation in astrocytes 
under normoxic and OGD/ reoxygenation for 24 h. (B) Same as (A) except that Akt 
phosphorylation was determined at 20 and 40 mins after reoxygenation. Intensity of pAkt 
signal was measured by scanning densitometry and normalized to total Akt at each of the 
control time points. Mean ± SD, n ≥ 3 independent cultures in duplicates. One-way ANOVA 
and post hoc Tukey's multiple comparison test. *P<0.05 **P<0.01 and ***P< 0.001 indicate 
statistically significant differences. 
 
4.4. FSAP treatment also modulates p53 and Bcl-2 expression downstream of Akt 
phosphorylation 
After ischemic injury, it is known that there is an increase in p53 levels which 
further potentiate cell death response. It has been described that there exists a cross-
talk between Akt and p53 which plays a critical role in cell survival after ischemia (Li 
et al., 2013). Also, it has been previously reported that restoring the levels of anti-
apoptotic Bcl-2 shifts the cellular response towards survival. Promoting Akt 
phosphorylation has been implicated to also up regulate Bcl-2 levels, further 
enhancing the cell survival response (Pugazhenthi et al., 2000; Bratton et al., 2010). 
Since we observed that FSAP treatment robustly induced Akt phosphorylation, we 
investigated further if FSAP treatment affected OGD/reoxygenation-mediated p53 
induction. FSAP reduced p53 expression dose dependently on astrocytes exposed to 
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OGD/reoxygenation (Figure 4.4A). Next, we checked if FSAP induced Akt 
phosphorylation had any effect on Bcl-2 expression. FSAP treatment indeed increased 
Bcl-2 protein (Figure 4.4A) after OGD/ reoxygenation injury in astrocytes. Thus, 
FSAP could prevent cell death by activating the PI3K/ Akt pathway that in turn 
influences the activity of p53 and Bcl proteins. 
 
4.5. The FSAP induced protective effect involves activation of protease-activated 
receptor-1 (PAR-1) 
Activated Protein C and Thrombin mediated cleavage of PARs leads to the 
activation of PI3K’s and promotes Akt phosphorylation in neurons, astrocytes and 
endothelial cells (Resendiz et al., 2007; Mosnier et al., 2012). Since it has been 
previously reported that FSAP can signal through PAR-1 receptor on endothelial cells 
(Mambetsariev et al., 2010) and PAR-1 is expressed on astrocytes, we checked if the 
FSAP-induced protection was mediated through the astrocytic PAR-1 receptor.  
In the presence of SCH 79797, a strong, selective non-peptide PAR-1 
antagonist, FSAP was unable to reduce cell death as measured by LDH release and 
mitochondrial function assay (Figure 4.4B & 4.4C). We also observed that FSAP 
induced Akt phosphorylation was blocked by treatment with SCH79797, indicating 
that PAR-1 is a receptor necessary for the protective effect of FSAP (Figure 4.4D).  
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Figure 4.4: FSAP inhibits cell death after OGD/reoxygenation by regulating p53 
and Bcl-2 expression via the PAR-1 receptor in astrocytes.  
A. Western blots for p53, Bcl-2 and β-actin in whole-cell extracts from astrocytes after 2 h of 
reoxygenation in the presence of FSAP (0-100 nM). Intensity of p53 and Bcl-2 signal was 
measured by scanning densitometry and normalized to β-actin. Relative expression in 
normoxic cells was set as 1. B-C. Survival of astrocytes 24 h after reoxygenation in the 
presence or absence of FSAP (100 nM) and SCH 79797 (5µM) was measured using LDH 
release assay (B) and MTT reduction assay (C). D. Representative Western blot for pAkt 
(Ser473) and total Akt in whole-cell extracts from the same experiment. Intensity of pAkt 
signal was measured by scanning densitometry and normalized to total Akt at 2 hours. 
SCH79797 was added to the culture 20 min before OGD exposure. Mean ± SD, n ≥ 3 
independent cultures in duplicates. One-way ANOVA and post hoc Tukey's multiple 
comparison test. *P<0.05 **P<0.01 and ***P< 0.001 indicate statistically significant 
differences. 
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4.6. FSAP modulates the expression of anti-inflammatory genes after 
OGD/reoxygenation in astrocytes 
Since astrocytes play a critical role in regulation inflammation post ischemia 
in stroke, we investigated if FSAP influenced the expression of inflammatory genes.  
We observed the FSAP significantly increased the mRNA expression of anti-
inflammatory IL-10 and IL-4 genes while down regulating the expression of pro-
inflammatory COX-2 and IL-6 genes after OGD/reoxygenation injury indicating an 
anti-inflammatory role for FSAP (Figure 4.5).  Similarly, FSAP decreased TNF-α 
expression after OGD/reoxygenation in astrocytes. Thus, FSAP could alter the 
inflammatory phenotype developed by ischemic astrocytes by promoting the 
expression of anti-inflammatory genes thereby reducing inflammation induced 
secondary cell death.  
 
 
Figure 4.5: FSAP treatment alters the mRNA expression profile of anti-
inflammatory genes in astrocytes.   
mRNA expression of different inflammatory genes was measured 24 hours after OGD/ 
reoxygenation in astrocytes. FSAP, PPACK-FSAP, Aprotinin were added as described in 
earlier sections. Mean ± SD, n ≥ 3 independent cultures in duplicates. One-way ANOVA and 
post hoc Tukey's multiple comparison test. *P<0.05, **P<0.01 and ***P< 0.001 indicate 
statistically significant differences. 
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4.7. FSAP protects astrocytes from hydrogen peroxide (H2O2) induced injury 
During oxidative stress, cell apoptosis is promoted through the mitochondrial 
death pathway. Hence we investigated the biochemical and morphological responses 
of astrocytes to hydrogen peroxide-mediated cell death and define the role that FSAP 
might play in the apoptotic cascade. Astrocytes were exposed transiently to H2O2 for 
3h, and cell death was measured 24 hours later. Cell death induced by H2O2 was 
reversed by FSAP treatment as measured using the LDH release (Figure 4.6A) and 
MTT assay (Figure 4.6B). Enzymatic activity of FSAP was required for this 
protective effect (Figure 4.6).  As in the OGD/reoxygenation model, FSAP treatment 
significantly increased the Akt phosphorylation and promoted the PI3K-Akt signaling 
pathway activation in the presence of H2O2 (Figure 4.6C). Similarly, the induction of 
caspase activity and apoptosis by treatment with H2O2 (Figure 4.7A, B, C) was also 
reduced by FSAP. This effect was mediated via PAR-1 signaling as showed using 
LDH (Figure 4.7D) and MTT assay (Figure 4.7E).   Thus, our results show that FSAP 
is able to promote cell survival in multiple form of ischemic injury in astrocytes and 
PAR-1 receptor mediated Akt phosphorylation by FSAP was responsible for the 
protective effect. 
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Figure 4.6: FSAP treatment prevents cell death and mitochondrial function via Akt 
phosphorylation in H2O2-treated astrocytes.  
Astrocytes were exposed to 250 µM H2O2 for 3 hours followed by 24 hours in the absence or 
presence of FSAP (100 nM) and APO (10 µg/ml). A-B. Cell viability was measured using 
LDH release assay (A) and MTT reduction assay (B). C. Representative Western blot for 
pAkt (Ser473) and total Akt in whole-cell extracts from the same experiment as above. Mean 
± SD, n ≥ 3 independent cultures in duplicates. One-way ANOVA and post hoc Tukey's 
multiple comparison test. **P<0.01 and ***P< 0.001 indicate statistically significant 
differences. 
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Figure 4.7: FSAP prevents apoptosis after oxidative stress injury in astrocytes by 
activating PAR-1 receptor.  
A. Representative fluorescent-TUNEL (green)/dapi (blue) staining in astrocytes 24 h in the 
presence or absence of FSAP (100 nM) after 3 h H2O2 treatment. B. Caspase-3 and -7 activity 
in astrocytes 12 h after H2O2 in the presence or absence of FSAP. C. The number of apoptotic 
TUNEL-positive cells quantified from the experiment in (A). D-E. Cell death was quantified 
by (D) LDH release and (E) Mitochondrial function assay in the presence or absence of FSAP 
and SCH79797, PAR-1 antagonist. SCH 79797 (5µM) was added to the culture 20 min before 
H2O2 treatment. Mean ± SD, n ≥ 3 independent cultures in duplicates. One-way ANOVA and 
post hoc Tukey's multiple comparison test. **P<0.01 and ***P< 0.001 indicate statistically 
significant differences. 
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4.8. FSAP protects mouse cortical neurons from tPA/NMDA-mediated injury 
Various studies using a transient ischemia stroke models have shown direct 
post-ischemic neuronal toxicity of tPA. It has been also shown that tPA enhances 
neuronal injury in the presence of NMDA. The pathologic activation of NMDARs 
contributes to neuronal death after acute excitotoxic trauma such as brain ischemia. 
To determine whether FSAP could influence neuronal death, we used a model of 
excitotoxicity induced by exposure of primary cortical neuronal cultures to NMDA 
(12.5 uM) in the presence of tPA (20 ug/ml) as has been reported previously (Roussel 
et al., 2011). tPA/NMDA treatment produced acute cell swelling followed 24 hours 
later by neuronal degeneration, as measured by the release of LDH in supernatant. 
Co-application of FSAP (100 nM) prevented the pro-excitotoxic effects of 
tPA/NMDA-induced neuronal death (Figure 4.8.1. A, C). Neuronal viability was also 
assessed using the MTT reduction assay as a measure of mitochondrial dysfunction 
(Reddrop et al., 2005), tPA/NMDA treatment reduced mitochondrial function 
whereas, FSAP preserved it (Figure 4. 8.1. B, C). 
We then checked if the increased survival of the cells was related to the 
process of apoptosis by measuring the enzymatic activity of caspase-3/7 as well as 
TUNEL assays. Treatment with FSAP blocked the tPA/NMDA-mediated activation 
of caspases (Figure 4.8.2.A). A few TUNEL-positive staining cells were noted in 
control cells whereas cultures treated with tPA/NMDA for 24 hours had a large 
numbers of cells undergoing apoptosis. However, FSAP treatment reduced the 
numbers of apoptotic cells (Figure 4.8.2.B, C). Inactivation of FSAP with aprotinin 
reversed the effect of FSAP (Figure 4.9.A, B). Thus the enzymatic activity of FSAP 
protected against tPA/NMDA excitotoxicity in neurons. 
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Figure 4.8.1:  FSAP protects neurons from tPA/NMDA-mediated injury. 
Effect of FSAP (100 nM) on neuronal cultures 24 h after tPA/NMDA treatment. FSAP was 
used at 100 nM and was added simultaneously with tPA (20 µg/ml) and NMDA (12.5 µM). 
Cell survival was quantified with a LDH assay (A) & MTT reduction assay (B) relative to 
normoxic controls (100%). FSAP treatment promoted cell survival in dose dependent manner 
in neuronal cultures 24 h after tPA/NMDA treatment as quantified by LDH assay (C) and 
MTT reduction assay (D) and expressed relative to normoxic controls (100%). For the dose 
response, cells were treated with 12.5 nM, 25 nM, 50 nM & 100 nM FSAP. Mean ± SD, n ≥ 3 
independent cultures in duplicates. One-way ANOVA and post hoc Tukey's multiple 
comparison test. *P<0.05 **P<0.01 and ***P< 0.001 indicate statistically significant 
differences. 
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Figure 4.8.2: FSAP treatment reduces apoptosis in neurons after tPA/NMDA-
mediated injury.  
(A) Caspase-3/-7 activity in neurons 12 h after tPA/NMDA in the presence or absence of 
FSAP. (B) The number of apoptotic TUNEL-positive cells quantified as described in the 
Methods in the presence of NMDA with and without tPA or FSAP. (C) Representative 
fluorescent-TUNEL (green)/dapi (blue) staining in neurons 24 h after tPA/NMDA treatment 
in the presence or absence of FSAP. Mean ± SD, n ≥ 3 independent cultures in duplicates. 
One-way ANOVA and post hoc Tukey's multiple comparison test. *P<0.05 **P<0.01 and 
***P< 0.001 indicate statistically significant differences. 
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Figure 4.9: Inactive FSAP does not protect neurons against tPA/NMDA 
excitotoxic injury.  
Survival of neurons 24 h after tPA/NMDA exposure in the presence/ absence of FSAP (100 
nM) and APO (10 µg/ml) was measured using (A) LDH release assay and (B) MTT reduction 
assay. In all experiments FSAP was added simultaneously with tPA (20 µg/ml) and NMDA 
(12.5 µM). Mean ± SD, n = 3 independent cultures in duplicates. One-way ANOVA and post 
hoc Tukey's multiple comparison test. ***P< 0.001 indicates statistically significant 
differences. 
 
4.9. FSAP neuroprotection requires activation of Akt signaling 
Various studies show that tPA/NMDA injury involves a decrease in Akt 
phosphorylation in neurons (Liu et al., 2004; Guo et al., 2011). We tested whether the 
ability of FSAP to protect neurons from tPA/NMDA-mediated injury requires PI3K-
Akt activation. FSAP treatment stimulated phosphorylation of Akt on Ser473 in 
neurons after tPA/NMDA challenge (Figure 4.10 A, B) indicating that FSAP is able 
to activate the Akt signaling pathway in a sustained manner. LY294002 and 
Wortmannin, PI3K inhibitors, blocked FSAP-mediated phosphorylation of Akt and 
neuronal protection after tPA/NMDA exposure as measured by LDH release (Figure 
4.11. E) and MTT reduction (Figure 4.11. F). This data suggests that FSAP’s 
neuroprotective effects are modulated through the PI3K-Akt pathway. Since it has 
been previously reported that tPA/NMDA induces p53 activation (Liu et al., 2004) 
and FSAP treatment increased Akt, we investigated if FSAP treatment had any effect 
of p53 induction. FSAP treatment, indeed, reduced the tPA/NMDA induced p53 
levels in excitotoxic neurons as seen in the representative western blot and its 
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densitometry analysis (Figure 4.10 A,C). FSAP treatment also increased Bcl-2 protein 
expression after tPA/NMDA injury (Figure 4.10 A, D) indicating a pro survival 
signaling pathway comprising of Akt/ p53/ Bcl-2. PAR-1 receptor antagonist, 
treatment blocked the FSAP induced neuroprotection as measured by LDH release 
and mitochondrial function (Figure 4.11. A, B respectively). FSAP down-regulation 
of caspase 3/7 activity (Figure 4.11 C), activation of Akt phosphorylation (Figure 4.11 
D,E) and up-regulation of anti apoptotic Bcl-2 protein (Figure 4.11 D,F) in 
tPA/NMDA treated excitotoxic neurons was also inhibited by the PAR-1 antagonist. 
 
Figure 4.10: FSAP protects neurons from tPA/NMDA excitotoxicity via Akt 
survival pathway.  
Representative western blots for pAkt (Ser473), total Akt, p53, Bcl-2 and β-actin in whole-
cell extracts from neurons 2 h (A) after tPA/NMDA exposure in the presence or absence of 
FSAP (100 nM). Intensity of pAkt signal was measured by scanning densitometry and 
normalized to total Akt at 2 hours. Intensity of p53 and Bcl-2 signal was measured by 
scanning densitometry and normalized to β-actin at 2 hours. Survival of neurons 24 h after 
tPA/NMDA exposure in the presence or absence of FSAP (100 nM), LY294002 (10 µM), 
Wortmannin (0.5 µM) was measured using (B) LDH release assay and (C) MTT reduction 
assay. LY294002 and Wortmannin were added to the culture 1 h before tPA/NMDA 
treatment. When applied alone, neither Wortmannin nor LY294002 was toxic. In all studies, 
FSAP was added simultaneously with tPA/NMDA. Mean ± SD, n ≥ 3 independent cultures in 
duplicates. One-way ANOVA and post hoc Tukey's multiple comparison test. *P<0.05 
**P<0.01 and ***P< 0.001 indicate statistically significant differences. 
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Figure 4.11: FSAP protects neurons from tPA/NMDA excitotoxicity via PAR-1 
receptor signaling.  
Survival of neurons 24 h after tPA/NMDA exposure in the presence or absence of FSAP and 
SCH 79797 (5µM) was measured using (A) LDH release assay and (B) MTT reduction assay. 
(C) Caspase-3/-7 activity in neurons 12 h after tPA/NMDA in the presence or absence of 
FSAP 100 nM and SCH79797 (5µM). (D) Representative western blots for pAkt (Ser473), 
total Akt, Bcl-2 and β-actin in whole-cell extracts from neurons 2 h after tPA/NMDA 
exposure. Intensity of pAkt signal and Bcl-2 was measured by scanning densitometry and 
normalized to total Akt and β-actin at 2 hours respectively SCH79797 was added to the 
culture 20 min before tPA/NMDA treatment. Mean ± SD, n ≥ 3 independent cultures in 
duplicates. One-way ANOVA and post hoc Tukey's multiple comparison test. *P<0.05 
**P<0.01 and ***P< 0.001 indicate statistically significant differences. 
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4.10. FSAP protects neurons from OGD-reperfusion damage  
To further validate the neuroprotective effect of FSAP, we subjected cortical 
neurons in culture to oxygen glucose deprivation (OGD) (90 min) followed by 24 
hours reperfusion with glucose containing medium. It is know that OGD exposure in 
neurons induces cell death via the apoptotic signaling which leads to activation of 
caspases and involves p53 accumulation. Cell death induced by OGD/reoxygenation 
was attenuated by FSAP treatment as measured by LDH release and MTT assay. 
Exactly, as with the excitototoxicity-mediated cell death, OGD induced cell death was 
reversed by blocking the enzymatic activity of FSAP (Figure 4.12 A, B). Also, FSAP 
regulated Akt phosphorylation and promoted PI3K-Akt signaling pathway (Figure 
4.12 C, D). Similarly, the down-regulation of caspase -3/-7 activity (Figure 4.13 E) 
and apoptosis (Figure 4.12 F,G) was reduced in the presence of FSAP and this effect 
could also be blocked by aprotinin. The neuroprotective effect of FSAP was mediated 
by PAR-1 dependent signaling as indicated by the LDH release (Figure 4.13 A) and 
mitochondrial function (Figure 4.13 B) in inhibitor treated cells. Also, FSAP failed to 
activate Akt survival pathway signaling (Figure 4.13 D, E) in the presence of SCH 
79797. FSAP induced reduction in p53 protein expression (Figure 4.13 D, F) was 
diminished with the treatment of the antagonist. FSAP failed to reduce Caspase 3 
activity in hypoxic neurons with the blockage of the PAR-1 signaling pathway (Figure 
4.13 C). 
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Figure 4.12: Inactive FSAP does not protect neurons from OGD/reoxygenation 
injury.  
Cell death was quantified by (A) LDH release and (B) MTT reduction assay from neurons 24 
h after 90 min exposure to OGD in the presence or absence of FSAP (100 nM). (C) 
Representative western blots for pAkt (Ser473) and total Akt in whole-cell extracts from 
neurons after OGD/ reoxygenation. (D) Intensity of pAkt signal was measured by scanning 
densitometry and normalized to total Akt. (E) Caspase 3/7 activity in neurons 12 h after 
OGD/ reoxygenation was reduced with FSAP (100 nM) treatment. (F) The number of 
apoptotic TUNEL-positive cells was quantified as described in the methods 24 hours after 
OGD in the presence or absence of FSAP. (G) Representative fluorescent-TUNEL (green)/ 
DAPI (blue) staining in neurons after OGD/ reoxygenation. 
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Figure 4.13: FSAP protects neurons from OGD/reoxygenation via PAR-1 receptor 
signaling.  
Cell viability was quantified (A) LDH release and (B) MTT reduction assay from neurons 24 
h after 90 min exposure to OGD in the presence or absence of FSAP (100 nM) and SCH 
79797(5µM). (C) Caspase-3/-7 activity in neurons 12 h after OGD in the presence or absence 
of FSAP and SCH 79797. (D) Representative western blots for pAkt (Ser473), total Akt, p53 
and β-actin in whole-cell extracts from neurons 24 hours after OGD/ reoxygenation. Intensity 
of pAkt and p53 signal was measured by scanning densitometry and normalized to total Akt 
and β-actin respectively. Mean ± SD, n ≥ 3 independent cultures in duplicates. One-way 
ANOVA and post hoc Tukey's multiple comparison test. *P<0.05 **P<0.01 and ***P< 0.001 
indicate statistically significant differences. 
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4.11. Endogenous FSAP influences stroke outcome in thromboembolic stroke 
model  
After having seen the protective effects of FSAP in-vitro on the cells of the 
BBB, we sought to analyze the role of FSAP using mouse stroke model. The 
development of neuronal damage in FSAP-/- mice following cerebral ischemia was 
studied in a model that depends on thromboembolism in the microvasculature of the 
middle cerebral artery (MCA). These experiments were conducted in cooperation 
with Prof. Denis Vivien/ Dr. Cyrille Orset at Cyceron, University of Caen, Caen, 
France. The advantage of this model compared to other embolic stroke models is the 
high reproducibility as the clot is always located at the same place.  
To initiate cerebral ischemia, murine thrombin, was directly injected into the 
MCA to form a stable clot in about 10 min and reduced the regional cerebral flow by 
>90%.  Post surgery, the mice were kept under anesthesia for a further 50 min on a 
heated pad at 37 0C. 24 h after the surgery, animals were analyzed for infarct volumes 
and reperfusion using MRI. To account for differences in the brain size, we measured 
the infarct volumes as % of contralateral hemisphere. We observed that infarct 
volumes 24 h after reperfusion were significantly increased in FSAP-/- mice compared 
to WT mice. The infarcted region appears more hyperintense in the T2-weighted 
images (Figure 4.14 A) .The infarct size of WT mice was 12.6 ± 4.09 % versus 18.6 ± 
5.35 % in FSAP-/- animals (Figure 4.14 B). All animals showed infarction that was 
restricted to the cortex. The lesion volume was distributed from the anterior (position 
+ 3.2 from the bregma) to the posterior brain (- 4.8 mm from the bregma) with a 
distribution that was homogeneous between animals.  
Next, edema formation was calculated as a ratio of Contralateral and 
Ispilateral hemispheres, which significantly correlates with absolute brain water 
content. This analysis revealed that FSAP-/- mice developed relatively pronounced 
cerebral edema as compared to WT mice (Figure 4.14 C). We then investigated 
whether the tissue damage in FSAP-/- mice was also functionally relevant. 
Neurological deficit was analyzed as described in the methods and we observed that 
FSAP-/- mice performed significantly worse compared to WT mice showing multiple 
deficits (Figure 4.14 D) correlating well with the increased infarct volumes.  These 
results obtained from the above experiments provide further evidence of the role of 
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FSAP in the pathophysiology of stroke and correlate well with the human population 
data wherein FSAP-MI patients are at more risk of fatal stroke. 
 
Figure 4.14: Loss of endogenous FSAP enhances infarct volumes and worsens 
stroke outcome.  
A. Longitudinal T2-weighted images for WT and FSAP-/- 24 hours after thromboembolic 
stroke indicating the infarcted area.  B. Infarct volumes are represented as % of the infarcted 
hemisphere. C. Edema formation was calculated as described in methods. Edema formation is 
represented as ratio of contralateral to the infarcted hemispheres. D. FSAP -/- show higher 
neural deficit as compared to WT. Data represented as mean ± SD. n=11 in each group. 
*P<0.05; Data from % Infarct (B) and edema (C) were analyzed with unpaired 2-tailed 
Student´s t-test; Neural deficit score (C) was evaluated with the Mann-Whitney-U test.  
 
 
4.12. FSAP -/- mice have cerebral vasculature comparable to WT mice 
Reperfusion plays a dual role after ischemia, while restoring the blood flow 
ensures the supply of O2, it also leads to the influx of leukocytes, neutrophils and 
other cells which further worsen the outcome.  Next, to check if the observed increase 
in infarct volumes was associated with decreased perfusion in the FSAP-/- mice, we 
evaluated the cerebral reperfusion after stroke. Using, laser doppler flowmetry, we 
evaluated the relative reperfusion in both hemispheres. However, there was no 
significant difference in the relative cerebral reperfusion 24 h after stroke onset in WT 
and FSAP -/- mice (Figure 4.15 A, B). Then using non-invasive MRI, we calculated 
Chapter 4. Results 
_____________________________________________________________________ 
 - 52 - 
the mean angiography score to evaluate existing embolism in the larger arteries, 
which revealed no difference between the WT and FSAP-/- mice (Figure 4.15 C, D). 
The MRI angiogram also revealed no difference in the cerebral vasculature of the WT 
and FSAP-/- mice (Figure 4.15 C) indicating that FSAP deficiency lead to poor 
outcome independent of fibrinolytic mechanism.   
 
Figure 4.15: Endogenous FSAP shows no effect on cerebral reperfusion after 
embolic stroke.  
A. LSF flux images (perfusion images) showing cerebral blood flow (CBF) post reperfusion 
in WT and FSAP -/- mice. B. No difference observed in the relative reperfusion in WT and 
FSAP-/- mice after stroke. C. Represenative angiogram showing cerebral vasculature in WT 
and FSAP -/- mice. D. Mean angiography score was calculated as described in methods and 
indicates no difference between WT and FSAP -/- mice.  Data represented as mean ± SD. n=11 
in each group. Data from % Reperfusion (B) and Mean angiography score (D) were analyzed 
with unpaired 2-tailed Student´s t-test. 
 
4.13. FSAP antigen and activity levels are elevated after stroke  
 Previously, we had reported that FSAP antigen and activity levels were 
elevated in human patients after ischemic stroke. In our model of thromboembolic 
stroke, we observed that the circulating levels of FSAP did increase appreciably 
(Figure 4.16 A, B) and the activity increased substantially (Figure 4.16 C) as 
compared to sham operated mice indicating a role for FSAP in recovery in the WT 
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mice. We could not detect any FSAP antigen or activity in the FSAP-/- mice 
confirming the associated increase in infarction was associated with the complete loss 
of FSAP.  
 
Figure 4.16: Endogenous FSAP levels are elevated after embolic stroke. 
A. Representative western blot for FSAP and Ceruloplasmin in mouse plasma in sham and 
stroke samples. B. Intensity of FSAP signal was measured by scanning densiometry and 
normalized to Ceruloplasmin. C. Circulating FSAP activity increased in mouse plasma in WT 
mice and was measured as described in methods.  Data represented as mean ± SD. 5 sham 
mice per group and 11 stroke mice per group were used for the analysis. One way anova 
followed by Tukey’s multiple comparison test. *P<0.05, ***<P<0.001.  
 
 
4.14. Increased pro-inflammatory cytokine transcription in FSAP -/- mice after 
stroke 
The inflammatory response in stroke involves not only leukocytes, endothelial 
and glial cells but also neurons. At the molecular level, inflammation is mediated by a 
complex cascade of mediators. Since in our earlier experiments with astrocytes we 
observed that FSAP influenced the expression of inflammatory genes, we analyzed if 
the increased infarct volumes were associated with the modulation of inflammation. A 
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strong up-regulation of TNF-α, IL-1β, IL-6 and COX-2 was observed at 24 h in the 
ischemic hemisphere after occlusion in WT and FSAP-/- mice. IL-6 is a pleiotropic 
cytokine that coordinates inflammatory processes between the periphery and the 
central nervous system, and can be released by various cell types in response to 
injuries. Moreover, IL-6 influences the expression and function of several other 
inflammatory mediators. Several studies have reported that higher levels IL-6 are 
associated with worse outcome after ischemic stroke (Cojocaru et al., 2009). IL-6 
expression was significantly higher in FSAP-/- mice as compared to WT mice.  
 
 
Figure 4.17: Expression of inflammatory genes is increased in after 
thromboembolic stroke 
mRNA expression of  TNF-α, IL-10, COX-2, IL-6, IL-4 and iNOS were analyzed by 
quantitative real-time polymerase chain reaction 24 after reperfusion. Mean fold increase was 
calculated relative to contralateral WT hemisphere (n-5).  Data represented as median. One-
way ANOVA and post hoc Tukey's multiple comparison test. *P<0.05 
 
Expression of IL-4, a potent anti-inflammatory cytokine was decreased further 
in FSAP-/-, while the expression of COX-2 was increased. The expression of iNOS 
mRNA tended to be elevated per se, however it was not significantly up-regulated in 
the FSAP-/- mice. Both injurious and beneficial roles of TNF-α have been proposed 
for TNF-α in the pathogenesis of cerebral ischemia (Pan and Kastin, 2007). However, 
no difference was observed in the TNF-α expression in WT and FSAP-/- mice. IL-10 
deficiency was shown exacerbates damage, while its over-expression reduced infarct 
volumes after ischemic brain injury (Planas et al., 2006). The post-ischemic IL-10 
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mRNA response was also not found to be significantly altered between the two 
groups.  There was however, a tendency towards a pro-inflammatory phenotype in the 
FSAP-/- mice after embolic stroke as represented in Figure 4.17, which suggests a 
possible role for FSAP in modulating post-ischemic inflammation and associated 
increase in infarct volumes. 
4.15. Endogenous FSAP modulates Akt phosphorylation in-vivo after embolic 
stroke 
Akt activation is one of the principal factors that prevent apoptosis in many 
cellular systems. In our in-vitro analysis, we observed that exogenous FSAP was able 
to prevent cell death in neurons and astrocytes after ischemic insults via up-regulation 
of PI3K-Akt signaling pathway. To study the role of endogenous FSAP on Akt 
phosphorylation, we performed western blot analysis of Akt phosphorylated at serine 
473 in brain extracts of WT and FSAP-/- 24 hours after stroke. Akt did not show a 
prominent modification after reperfusion. However, Akt phosphorylation was 
significantly down-regulated in ipsilateral hemisphere of FSAP-/- mice and also 
showed a tendency towards decrease in the contralateral hemisphere confirming the 
in-vitro findings that FSAP appears to be an activator of Akt survival signaling 
pathway (Figure 4.18).    
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Figure 4.18: Western blot analysis of phospho-Akt (serine-473) and Akt from WT 
and FSAP -/- mice after embolic stroke.  
(A) Representative Western blot analysis for Akt phosphorylated at serine 473 (pAkt) and 
total Akt in brain extracts from WT and FSAP-/- mice 24 hours after stroke. (B) Mean density 
of the band for pAkt in wild-type and FSAP-/- mice 24 hours after occlusion as measured by 
scanning densiometry. n = 6.  Data represented as Mean ± SD.  One-way ANOVA and post 
hoc Tukey's multiple comparison test. *P<0.05 
 
4.16. FSAP regulates p53 and Bcl-2 protein levels in mice after stroke  
Pro-apoptotic p53 expression after ischemic stroke is one of the most 
prominent markers of the extent of cell injury (Vaseva et al., 2012). We observed that 
the protein levels of p53 were increased in the occluded hemispheres of WT and 
FSAP-/- mice as compared to the contralateral hemisphere. However, significant 
increase in the p53 levels in FSAP-/- mice as compared to WT indicated the severity of 
the ischemic injury suggesting a role for endogenous FSAP in modulating p53 levels 
in-vivo (Figure 4.19 A,B). Since p53 and anti-apoptotic Bcl-2 participate in the 
modulation and execution of cell death, we investigated whether there were changes 
in its protein expression. Our results indicate that the protein expression of Bcl-2 in 
the FSAP-/- mice is significantly reduced compared to WT mice in the occluded 
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hemisphere after stroke (Figure 4.19 A,C). These results confirm our in-vitro findings 
wherein exogenously added FSAP via Akt phosphorylation was able to reduce the 
p53 expression while increased anti-apoptotic Bcl-2 protein expression in neurons and 
astrocytes under ischemic conditions. 
 
Figure 4.19: Western blot analysis of Bcl-2 and p53 from WT and FSAP -/- mice 
after embolic stroke.  
(A) Representative Western blot analysis for Bcl-2, p53 and GAPDH in brain extracts from 
WT and FSAP -/- mice 24 hours after stroke (B) Mean density of the band for pAkt in wild-
type and FSAP-/- mice 24 hours after occlusion as measured by scanning densiometry. n = 6.  
Data represented as Mean ± SD.  One-way ANOVA and post hoc Tukey's multiple 
comparison test. *P<0.05 
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5. Discussion 
Ischemic stroke is one of the leading causes of mortality and economic burden 
across the globe (Moskowitz et al., 2010). About 85% of all strokes are ischemic and 
occur due to decreased or complete loss of arterial blood supply to the brain 
culminating in a brain infarction. Arterial occlusion is most commonly caused by a 
thrombus, which can either form locally at the site of occlusion and partially or 
completely interrupt the blood supply (thrombotic stroke), or form in another part of 
the circulation and then follow the blood stream until it obstructs arteries in the brain 
(embolic stroke). This free-roaming clot is called an embolus and often forms in the 
heart or on atherosclerotic plaques in large arteries, e.g. cervical arteries or aortic 
arch.  
FSAP-MI is a significant risk predictor for the evolution and progression of 
carotid stenosis (Willeit et al., 2003). It was also shown that the FSAP-MI SNP is 
associated with an increased risk for clinical stroke and stroke related mortality 
(Trompet et al., 2011). They observed that Marburg I associated increase in mortality 
was mainly due to the increased risk of fatal stroke. The observed increase in stroke 
risk in Marburg I patients could be due to hyper proliferation of smooth muscle cells, 
since FSAP can inhibit PDGF-BB induced proliferation. FSAP through prothrombotic 
mechanisms, perhaps by activation of FVII (Kanse et al., 2008) and/or inhibition of 
TFPI (Kanse et al., 2012) could also contribute to the pathophysiology of ischemic 
stroke. Inflammatory responses play a critical role in the post stroke outcome. FSAP 
was shown to have an anti-inflammatory effect in bile duct model of liver fibrosis 
which is known to produce hypoxic conditions (Borkham-Kamphorst et al., 2013). 
This protective effect was lost in FSAP-/- mice  which suggests a potential role for 
FSAP in modulating inflammation in stroke patients and the absence of which might 
lead to heightened post stoke inflammation worsening the outcome. 
Recently, we showed that FSAP antigen and activity are elevated in patients 
with ischemic stroke (Hanson et al., 2012). We postulate that this might be due to the 
presence of cellular debris such as nucleic acids, histones and post-apoptotic cells that 
activate FSAP (Kanse et al., 2008). Since, 5% of Europeans are carriers of FSAP-MI 
there is a compelling case for further investigations into the pathophysiological role of 
FSAP in ischemic stroke. Hence in the present study, we investigated the role of 
FSAP in detail using both in-vitro and in-vivo strategies to elucidate the mechanisms 
and physiological role of FSAP in the context ischemic stroke.  
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5.1. FSAP and the blood brain barrier 
In-vitro BBB models are valuable and easy to use supporting tools that can 
precede and complement animal and human studies. Since, the immortalized brain 
endothelial cell lines fail to show BBB-specific property of being able to form a tight 
permeability barrier under culture conditions, BBB models consisting of primary 
brain endothelial cells are better suitable for studying transport mechanisms across the 
BBB in-vitro (Garberg et al., 2005). Most of these well known models use primary 
endothelial cells from different sources, bovine, porcine, rat, and even human brain 
tissues. However, only a few models exist with primary endothelial cells derived from 
mouse brain (Deli et al., 2005). Hence, we used a model described by Coisne et al 
(Coisne et al., 2005) and further validated by Prof. Britta Engelhardt and colleagues 
that uses primary mouse brain microvascular endothelial cells (pMBMECs) in co 
culture with primary mouse astrocytes (Gorina et al., 2013). In this model, the 
pMBMECs form a fully differentiated endothelial monolayer with preserved 
characteristics of the CNS microvasculature, such as complex tight-junctions and 
barrier formation due to the addition of abluminal astrocytes, thereby inducing a 
phenotype closely mimicking to that found in-vivo.  Recently, Steiner et al  also 
demonstrated that pMBMECs were much better model to the study of T cell 
extravasation as compared to the immortalized bEND5 cells since they better reflect 
the in-vivo protein expression of tight junctions (Steiner et al., 2011). 
 Normally, the tight junctions severely restrict penetration of water-soluble 
compounds. However, lipid-soluble agents effectively diffuse due to the large surface 
area of the lipid membranes of the endothelium. The endothelium also contains 
transport/ carrier proteins for glucose, amino acids, purine bases, nucleosides, choline 
and other substances (Abbott et al., 2006). Some of these transporters are energy-
dependent and act as efflux transporters.  Most proteins in the plasma are unable to 
cross the blood brain barrier due to their size and hydrophilicity. However, 
concentrations of certain proteins, such as insulin, insulin-like growth factors and 
transferrin, vary as the plasma concentrations change, and uptake of these peptides in 
the brain is greater than expected based on their size and lipid solubility by a process 
called receptor-mediated transcytosis (Abbott et al., 2006). Polycationic proteins and 
lectins can cross the blood brain barrier by a nonspecific yet similar process called 
absorptive-mediated transcytosis (Abbott et al., 2006). Thus, transmembrane 
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diffusion, harnessing of transporters, adsorptive endocytosis, and extracellular 
pathways are some of the mechanisms by which various molecules reach the brain 
parenchyma. 
 By using a brain vascular perfusion technique, Rashid Deane and colleagues 
showed that 125I-labeled plasma-derived mouse APC entered the brain from 
cerebrovascular circulation by a concentration-dependent mechanism (Deane et al., 
2009). Their data suggested that APC and its variants with reduced anticoagulant 
activity crossed the BBB via EPCR-mediated saturable transport. In other studies, tPA 
was shown to cross the BBB via LRP dependent (Benchenane et al., 2005b) and 
independent mechanisms irrespective of its proteolytic activity (Benchenane et al., 
2005a). López-Atalaya and colleagues showed that Desmoteplase, a recombinant 
form of the plasminogen activator DSPAα1 from Desmodus rotundus, crossed the 
intact BBB by LRP-mediated transcytosis and this mechanism remained unaltered 
after OGD exposure (Lopez-Atalaya et al., 2007). Thus, certain plasma proteins are 
able to cross the BBB through diverse mechanisms. 
Since FSAP is a plasma protease circulating with concentration of 12 µg/ml 
(180 nM) and no detectable expression in the brain (Kanse et al., 2008), it was first 
essential for us to establish if FSAP could cross the blood brain barrier. To this end, 
we used an in-vitro model of the BBB comprising of pMBMECs and astrocytes. In 
order to validate our model, we first measured the barrier permeability to FITC-
dextran. Permeability coefficient obtained from the passage of dextran is an accurate 
estimation of the barrier integrity and suitability. An incomplete barrier tends to have 
higher permeability due to the improper expression of tight-junctions or due to lack of 
adequate cells to form a complete barrier. The model used in this study had a 
permeability coefficient of 0.2 x 10-3 cm/ min which corresponded to the permeability 
coefficient calculated in earlier experiments (Gorina et al., 2013). We used maximum 
dose of 100 nM FSAP in our experiments based on the observation that, under pro-
inflammatory conditions only 18-40% of FSAP was activated and subsequently 
formed complexes with inhibitors (Yamamichi et al., 2011). To measure if FSAP 
crossed the in-vitro BBB, we added FSAP to the luminal side and collected samples 
from the abluminal side of the BBB. Using a FSAP ELISA, we observed that FSAP 
was able to cross the in-vitro BBB under normal conditions. However, the exact 
Chapter 5. Discussion 
_____________________________________________________________________ 
 - 61 - 
mechanism by which FSAP could cross the barrier was not further defined in this 
study. 
We further investigated if FSAP played any role in the post hypoxic regulation 
of the BBB. The BBB has a critical role in maintaining homeostasis in the central 
nervous system. OGD/reoxygenation is an in-vitro model that has been used to 
mimick conditions of ischemic stroke. This model is well suited to analyze the 
molecular mechanisms and physiological changes that occur post ischemia. The OGD 
model consists of replacing the conventional culture medium by another medium 
without glucose and transferring the cells to a temperature controlled hypoxia 
chamber connected to a constant N2 flux maintained in a humidified atmosphere with 
0-2% O2. Reperfusion is then performed which consists of replacing the OGD 
medium with a glucose-containing medium and then maintaining the cells in  
normoxic incubator to mimic the establishment of the brain blood flow and post-
stroke reoxygenation. In this in-vitro system, low oxygen pressure, low nutrient levels 
(glucose), and the accumulation of cellular products that are thought to contribute to 
damage during ischemia occur thus effectively mimicking the clinical situation 
(Camos and Mallolas, 2010).  
Studies have shown that hypoxia increased the permeability to FITC-labeled 
dextran in an in-vitro model of the blood–brain barrier consisting of brain 
microvascular endothelial cells (Li et al., 2010; Liu, J. et al., 2012). Previous 
investigations have documented that disorganization of tight-junction proteins are 
likely to occur within hours to days after ischemia, especially in models of ischemia 
followed by reperfusion. Zonula occludens-1 (ZO-1), occludin, claudin-5 proteins are 
important components of tight-junction structure and are implicated in the 
maintenance of integrity of tight-junctions (Jiao et al., 2011). ZO-1 links 
transmembrane proteins of the tight-junction to the actin cytoskeleton (Zehendner et 
al., 2011). Thus, changes in ZO-1 expression can accurately reflect the pathological 
changes of BBB, making it a valuable marker of endothelial barrier. It was shown that 
hypoxia disrupts the continuous pericellular distribution of the tight junction protein 
ZO-1 and this absence of ZO-1 is one of the mechanisms by which hyper permeability 
is produced (Zehendner et al., 2011).  
Chapter 5. Discussion 
_____________________________________________________________________ 
 - 62 - 
We observed that FSAP improved cell survival of the pMBMECs and also 
preserved the junction expression of ZO-1. This in turn translated to improve the 
barrier function as measured by the decreased dextran passage. Inactivating FSAP 
failed to improve cell survival, ZO-1 junctional expression and BBB permeability to 
dextran after OGD/ reoxygenation. Surprisingly, significantly higher levels of FSAP 
crossed the barrier after OGD/ reoxygenation while improving the permeability.  
5.2. FSAP protects against cell death and apoptosis in astrocytes 
It has now become increasingly clear that the interplay between astrocytes and 
neurons is critical in determining the infarct volume following a stroke. Astrocytic 
survival post ischemia is important since they have many functions that support the 
viability of neurons. Also due to the difference in their cellular metabolism, neurons 
are more susceptible to ischemia than astrocytes. Thus, strategies targeting astrocyte 
survival can help salvage the ischemic tissue. Since, from our earlier results we 
observed that FSAP could cross the BBB, we investigated if FSAP could influence 
cell survival in astrocytes. For this, we used two models of cell death induction, OGD 
and hydrogen peroxide (H2O2) injury. Using mitochondrial function assays and LDH 
release, we observed that FSAP treatment could improve cell survival under both 
forms of injury. FSAP also diminished the ischemia induced caspase 3/7 activity in 
stressed astrocytes. 
In order to further investigate the mechanisms involved in the protection, we 
analyzed the PI3K-Akt survival pathway. Multiple studies have shown that targeting 
this pathway promotes cell survival under ischemic conditions (Zhao et al., 2006; Xie 
et al., 2013). Akt activity is suggested to be up-regulated by phosphorylation through 
the activation of receptor tyrosine kinases by growth factors (Zhao et al., 2006). 
Although the upstream signaling components PDK-1 and integrin linked kinase 
enhance the activity of Akt, phosphatase and PTEN are known to decrease it. Upon 
activation, Akt phosphorylates an array of other molecules, including Bcl-2-
associated death protein, thereby blocking mitochondrial cytochrome c release and 
resultant caspase activity. Generally, the level of Akt phosphorylation at site Ser473 
has been reported to transiently increase after focal ischemia, while the levels of 
phosphorylation of PTEN, PDK1, forkhead transcription factor, and GSK3β 
decreased (Zhao et al., 2006). Gottlieb and colleagues demonstrated that depending on 
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the balance of signals, p53-dependent down-regulation of Akt may promote an 
irreversible commitment to apoptotic cell death, whereas effective recruitment of Akt 
by appropriate survival signals may lead to activation of Mdm2, inactivation of p53, 
and eventually inhibition of p53-dependent apoptosis thus promoting cell survival 
(Gottlieb et al., 2002). Also, Bcl-2 and its related family member Bcl-xL are among 
the most powerful death-suppressing proteins and inhibit both caspase-dependent and 
caspase-independent cell death. Akt phosphorylation is known to increase the 
endogenous expression of Bcl-2 proteins (Pugazhenthi et al., 2000). 
Our data shows that the FSAP mediated protection after hypoxia was indeed 
by phosphorylating Akt leading to a protective signaling cascade in a dose dependent 
manner (12.5 nM – 100 nM) with 100 nM showing the maximal protective effect. We 
observed that FSAP blocked the p53 mediated cell death via Akt phosphorylation. 
p53 blockade is known to reduce BAX levels in turn promoting an increase in anti-
apoptotic Bcl-2 levels. FSAP via Akt phosphorylation and p53 down-regulation was 
able to up regulate Bcl-2 protein levels thereby promoting cell survival post ischemia.  
Having defined the pathway by which FSAP mediates its protective effects, 
we decided to investigate the receptor upstream of PI3K with which FSAP might 
interact. Since it has been previously shown that FSAP can signal via PAR-1 
receptors on endothelial cells, enhanced expression of PAR-1 has been reported on 
astrocytes and neurons under ischemia (Rohatgi et al., 2004) , we focused on this 
candidate receptor. Protease-activated receptors are a subfamily of related G protein-
coupled receptors that are activated by cleavage of part of their extracellular domain 
by coagulation proteases and play an important role in modulating cellular responses 
in endothelial and other cells.  Thrombin (high dose)-PAR1 signaling has well 
established pro-inflammatory effects, including disruption of endothelial barrier 
function (Bae et al., 2009). However, incubation of an endothelial monolayer with 
APC as well as very low concentrations of thrombin potently enhanced barrier 
integrity through PAR1-dependent transactivation of the barrier protective 
sphingosine 1-phosphate (S1P) signaling pathway (Feistritzer and Riewald, 2005). It 
was also reported that APC-PAR1, but not thrombin-PAR1, downregulated transcript 
levels of several pro-apoptotic proteins including p53 and thrombospondin-1 
(Resendiz et al., 2007). It was also shown that cleavage of PAR-1 by APC and 
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thrombin leads to the activation of phosphatidylinositol-3-kinases (PI3Ks) and 
downstream Akt signaling pathway (Guo et al., 2013). Thus, activating PAR-1 can 
lead to diverse cellular outcomes based on the stimulus. 
We observed that blocking this receptor with an antagonist, SCH79797, 
completely removed the protective effect of FSAP. We also observed that abolishing 
the activity of FSAP with PPACK or Aprotinin, removed the protective effect of 
FSAP. FSAP also protected the astrocytes from H2O2 induced oxidative stress injury 
via the activation of PAR-1 mediated Akt phosphorylation and subsequent down-
regulation of p53 and caspase 3/7 activity. 
Astrocytes play a crucial role in modulating inflammation after hypoxic injury 
(Ceulemans et al., 2010). In earlier studies, we observed an anti-inflammatory role for 
FSAP in liver fibrosis. Hence, we investigated if FSAP played a role in attenuating 
the astrocytic inflammatory response.  We observed that FSAP was able to 
significantly down regulate pro-inflammatory IL-6, COX-2, iNOS and TNF-α gene 
expression while up-regulated  the expression of IL-4 and IL-10 anti-inflammatory 
genes indicating a shift in inflammatory phenotype in astrocytes after OGD 
reperfusion injury. This effect was modulated only by the active variant of FSAP 
indicating a secondary mechanism of protection conferred by FSAP in ischemic 
stroke.  
5.3. FSAP prevents cell death and apoptosis in cortical neurons  
 Devastating loss of neurons occurs in stroke, which triggers a series of 
complex cascades that leads to total breakdown of cellular integrity and eventually 
cell death. Multiple mechanisms have been identified that contribute to the loss of 
neurons in the penumbra. Promoting neuronal survival post ischemia has thus become 
an important target for therapeutic intervention.  After ischemic stroke, neurons are 
the most susceptible to damage in the peri-infarct region, with excitotoxicity being a 
key component. Normally, extracellular levels of glutamate are highly regulated by 
brain cells via glutamate transporters. Excess glutamate which is released from the 
injured cells disturbs this balance and results in hyper depolarization of neurons 
leading to necrosis and apoptosis (Nakka et al., 2008). Furthermore, tPA, the primary 
thrombolytic agent in treatment of ischemic stroke, is known to cross the blood brain 
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barrier and enhance this damage. It has been proposed that tPA cleaves the NR1 
subunit of NMDARs potentiating NMDA-induced calcium influx and neurotoxicity 
or that NR2D-containing NMDARs mediate tPA-induced neuronal excitotoxicity 
(Parcq et al., 2012). Thus preventing this excitotoxicity is of utmost scientific 
significance.  
 
 
Figure 5.1. Effect of FSAP on astrocytes, neurons and the blood brain barrier.  
FSAP was able to influence cell death and apoptosis in astrocytes, neurons and pMBMECs 
exposed to conditions mimicking stroke.  We observed that FSAP increased cell survival in 
neurons and astrocytes by regulating the PI3K-Akt pathway signaling mediated via PAR-1 
receptor increasing the Bcl-2 expression and preventing p53 accumulation. In pMBMECs, we 
observed that FSAP reduced endothelial permeability via reducing cell death and preventing 
ZO-1 translocation to the nuclei thus maintaining the tight-junction structure after OGD/ 
reoxygenation injury.  
 
Cell death after hypoxic injury is primarily thought to be due to the 
overstimulation of NMDA- receptors and hypoxia induced apoptosis (Lipton, 1999; 
Won et al., 2002). Neurons from mice genetically deficient in caspase 3 are relatively 
resistant to cell death caused by oxygen-glucose deprivation in-vitro and to mild brain 
ischemia after middle cerebral artery occlusion (Le et al., 2002). Various studies have 
reported that p53 is an important upstream initiator of excitotoxic NMDA-induced 
neuronal death and that it can increase Bax/Bcl-2 pro-apoptotic ratio through 
transcriptional Bax up-regulation and/or Bax oligomerization thus increasing cell 
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death (Liu et al., 2004; Guo et al., 2011). Depending on the stimulus intensity and 
neuronal cell type, some death pathways usually dominate over the others. Thus, after 
having seen the protective effect of FSAP on primary astrocytes and the blood brain 
barrier, we investigated if FSAP conferred the protection to primary cortical neurons 
under conditions mimicking ischemic stroke. 
In the current study, we used two models of neuronal damage, tPA/NMDA 
excitotoxicity or OGD/ reoxygenation. Consistent with the earlier reports, we 
observed that overstimulation of NMDA receptor with tPA/NMDA as well as 
OGD/reoxygenation increased caspase 3/7 mediated cell death (Plesnila et al., 2001; 
Le et al., 2002; Zhong et al., 2010) . FSAP was able to reverse this caspase activation 
thereby promoting neuronal survival. Our data indicates that FSAP was able to 
improve mitochondrial function in neurons. Proteolytic activity of FSAP was required 
for this neuroprotective effect.  As in astrocytes, FSAP was able to phosphorylate and 
sustain the Akt survival pathway in neurons. We observed that FSAP treatment 
reversed the accumulation of p53 in neurons post injury, presumably by regulating 
MDM2 and also restored the Bcl-2 protein levels. This effect was mediated via PAR-
1 receptor and similar to the previous observations in astrocytes and APC. Thus in 
this thesis, we present a neuroprotective signaling pathway involving PAR-1-Akt-
p53-Bcl-2 which FSAP can regulate in neurons under hypoxic injury. However, 
whether FSAP can act directly on NMDARs to attenuate the neurotoxic signaling 
during a tPA/NMDA-mediated insult should be addressed by the future studies. 
 
5.4. FSAP -/- mice have worsened outcome after embolic stroke 
Even though in-vitro models of ischemia/ reperfusion injury mimick the 
clinical situation, their role is limited to characterization of the pathways involved in 
the progression of injury or providing targets for neuroprotective agents since they are 
isolated systems devoid of any plasma mediators of injury. Rodent stroke models 
hence are the experimental standards for the in-vivo determination of the mechanisms 
of cell death and neural repair, and for the initial testing of neuroprotective 
compounds. Models of cerebral ischemia can be categorized into focal and global 
ischemia models. Focal ischemia is characterized by a reduction of cerebral blood 
flow in a distinct region of the brain, whereas in global ischemia the reduction of 
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blood flow affects the entire brain or forebrain (Carmichael, 2005; Durukan and 
Tatlisumak, 2007). In focal cerebral ischemia, either an artery or vein is occluded 
mechanically or by cerebral thromboembolism. Stroke caused by an acute cerebral 
vessel occlusion can be reproduced by different techniques, namely by mechanical 
occlusion of either the proximal middle cerebral artery (pMCAo) (large vessel 
occlusion) or distal MCA (dMCAo) (small vessel occlusion), or by thrombotic 
occlusion either via injection of blood clots or thrombin into the MCA (Durukan and 
Tatlisumak, 2007; Orset et al., 2007).  
Since majority of the ischemic strokes are of embolic origin, we used a model 
of in-situ thromboembolic stroke developed by Dr. Cyrille Orset and colleagues 
(Orset et al., 2007). In this model, embolism was induced by the local injection of 
murine purified thrombin into the middle cerebral artery that results in reproducible 
ischemic brain damage. MRI provides a non-invasive method to estimate the infarct 
volumes which help minimize the use of animals. T2 weighted images obtained from 
the MRI display the infarcted area as a hyper intense region. To account for 
differences in total brain volumes, we analyzed the infarcted area as percentage of the 
contralateral hemisphere. We observed that FSAP-/- mice had larger infarctions 
compared to WT mice 24 hours post injury. Larger infarct volumes have been 
associated with worsened neurological deficits in mice. The increased infarct volume 
that we observed in the FSAP-/- mice significantly correlated with worsened 
neurological deficit.  Even though all our mice survived the 24 hours end point, these 
results correlated with the clinical findings of FSAP-MI and increased risk of stroke.  
Since, higher infarct volumes have been associated with secondary edema 
formation, we then evaluated if FSAP-/- mice showed the presence of edema. Edema 
formation occurs post ischemic stroke which further accelerates the pathological 
outcome. This occurs due to the influx of neutrophils and leukocytes during 
reperfusion which enhances the MMP-9 expression in the brain leading to increased 
vascular permeability (Ludewig et al., 2013). After thromboembolic stroke, FSAP-/- 
mice exhibited a tendency towards edema formation as measured by the contralateral 
vs ispilateral ratio which indicated the increased space occupying effect due to higher 
water accumulation.  
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Then we investigated if the increased infarct volumes in FSAP-/- mice were 
associated with deficient reperfusion in the cerebral vasculature, since FSAP has a 
potential role in coagulation and hemostasis via modulating TFPI. In our model of 
thromboembolic stroke, it has been reported that the endogenous fibrinolytic pathway 
is activated within 1 h after the onset of stroke and the clot resolution is completed 
within 24 hours. Laser speckle flowmetry (LSF) is useful to noninvasively assess two-
dimensional cerebral blood flow (CBF) with high temporal and spatial resolution 
(Strong et al., 2006). We compared the difference in the flow between the two 
hemispheres and observed that 24 hours post ischemic event, there was no difference 
in the relative cerebral reperfusion in WT and FSAP-/- mice.  
MR angiography using a time-of-flight technique can be used to visualize the 
incomplete resolution of blood flow after MCA occlusion. The arterial vascular 
supply of the mouse brain can also be clearly analyzed by using 3D MR angiography 
and thus define the cerebral anatomy (Langhauser et al., 2012). Using a predefined 
protocol, we analyzed the WT and FSAP-/- mice post stroke to visualize the deficits in 
the cerebral vasculature and observed no significant difference in occluded blood 
vessels.   Magnetic resonance angiograms also revealed no difference in the cerebral 
vasculature of the FSAP-/- mice.  
In stroke, it has been reported that the circulating levels of nucleosomes is 
elevated (Geiger et al., 2006; Geiger et al., 2007). Similarly, it was shown that plasma 
DNA concentrations correlated with stroke severity (Rainer et al., 2003).  Since FSAP 
is activated by these factors; we analyzed the mouse plasma from WT and FSAP-/- 
mice in this study. We observed significantly elevated levels of FSAP antigen and 
activity in the WT mice 24 hours after embolic stroke. These results provide further 
support to the idea that endogenous active FSAP plays a critical role in the 
pathophysiology of stroke and correlated with the clinical observations wherein FSAP 
antigen and activity levels were elevated after ischemic stroke.  
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Figure 5.2. Effects of endogenous FSAP on stroke outcome.  
Absence of endogenous FSAP resulted in increased infarct volumes and neural deficits in 
FSAP-/- mice. No apparent differences were observed in cerebral vasculature and reperfusion 
post thromboembolic stroke in WT and FSAP-/- mice. However, Akt phosphorylation and 
subsequent Bcl-2 expression was significantly reduced in FSAP-/- mice. Also, p53 
accumulation was significantly higher in FSAP-/- mice indicating a failure in protection and 
higher cell death after thromboembolic stroke.  
Next we investigated if FSAP influenced the transcription of inflammatory 
genes in the brain after ischemic insult since FSAP was shown recently to have an 
anti-inflammatory role in liver fibrosis. In inflammation after cerebral ischemia, pro-
inflammatory cytokines, IL-6, TNF-α and reactive oxygen species are released by 
necrotic and injured tissue. Consequently, astrocytes, microglia and endothelial cells 
(EC) are activated which initiates the post-ischemic inflammatory response. In FSAP-
/-
 mice, we observed that the IL-6 mRNA expression was pronouncedly up-regulated. 
Even though, FSAP deficiency did not significantly alter the expression of TNF-α, IL-
10, IL-4, COX-2 and iNOS, there was a tendency towards pro-inflammatory 
phenotype in FSAP-/- mice after stroke, thus providing a parallel cascade for limiting 
neuronal damage. 
Having described the mechanisms for FSAP mediated neuroprotection in both 
neurons and astrocytes; we investigated if endogenous FSAP provided 
neuroprotection by regulating phosphorylation of Akt in-vivo. We observed that in 
FSAP-/- mice, phosphorylated Akt protein levels were significantly reduced as 
compared to WT mice 24 hours after embolic stroke.  We also observed higher levels 
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of p53 protein accumulation and reduced levels of anti-apoptotic Bcl-2 in the 
infarcted hemisphere in FSAP-/- mice in comparison with WT infarcted hemispheres 
further providing evidence to the observation that FSAP-/- mice have increased infarct 
volumes.  Thus from the data presented in this thesis, we show that endogenous FSAP 
plays an important role in the pathophysiology of ischemic stroke and has been 
summarized in Figure 5.2. 
5.5 Conclusions 
As the population ages, the number of ischemic stroke events are expected to 
rise and increase the socio-economic burden. In previous studies, FSAP-MI variant, 
5% of Caucasian population, was found to be a significant risk predictor for carotid 
stenosis, ischemic stroke and cardiovascular disease. We had also observed elevated 
plasma levels of FSAP antigen and activity in human stroke patients.  Thus, 
elucidating the role of FSAP in stroke is of importance. In the present study, we 
described a mechanism by which FSAP might influence stroke outcome and have 
been summarized in Figure 5.3. 
With the herein presented data new findings that shed light on the complex 
mechanism by which active FSAP modulates ischemic stroke are provided. We have 
shown that FSAP protected the blood brain barrier (BBB) exposed to conditions 
modeling ischemic stroke in-vitro. We propose that FSAP can preserve barrier 
integrity after ischemia and concomitantly it can cross the endothelial BBB and 
activate the canonical pro-survival Akt pathway in astrocytes and neurons. In 
response to OGD/reoxygenation or oxidative stress or excitotoxicity, only the 
enzymatically active FSAP protected neurons and astrocytes, while enzymatically 
inactivated FSAP was ineffective. Active FSAP also modulates post stroke 
inflammatory responses.  
In the final part of this study, we have shown the endogenous FSAP is 
essential in determining the stroke outcome. FSAP -/- mice showed more pronounced 
infarct volumes and neurological deficits, which could not be attributed to defective 
perfusion. Hence, we investigated at molecular level the role of endogenous FSAP in 
brain infarct evolution. Endogenous FSAP was essential for the activation of Akt 
survival pathway which leads to the subsequent observations in p53 and Bcl-2 levels.   
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Figure 5.3: Active FSAP protects the cells from Ischemia and limits infarct volume. 
After embolic stroke, the BBB permeability increases which leads to the efflux of dead cells 
and factors released by them into circulation. FSAP which circulates as an inactive zymogen 
is then activated and more FSAP crosses the BBB. During this process, FSAP stabilizes the 
BBB and reduces the permeability. Once in the brain parenchyma, FSAP activates the PAR-1 
receptor and induces phosphorylation of Akt which further leads to increased Bcl-2 and 
decreased p53 levels. This pathway prevents cell death and apoptosis. However, inactive 
FSAP as in the case of FSAP-MI patients, crosses the BBB but fails to reduce permeability. 
In the brain parenchyma, it fails to activate the PAR-1 receptor mediated Akt 
phosphorylation. Subsequently, there is accumulation of p53 which results in increased cell 
death.  
 
FSAP-MI SNP is associated with low proteolytic activity and has been 
associated with increased risk of ischemic stroke. We observed that only active FSAP 
could induce Akt phosphorylation in neurons, astrocytes and mouse brain; and leading 
to a subsequent protective effect (Figure 5.3). Failure of the FSAP pathway 
exacerbates the damaging consequences of ischemic stroke and perhaps is the reason 
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why MI-carriers, with low FSAP enzymatic activity are associated with an increased 
risk of clinical stroke and mortality.  
Although we were able to shed more light on the in-vitro and in-vivo effects of 
FSAP in the ischemic brain, this work was just the beginning of more complex and 
refined methodical studies in the future. Future studies should confirm these findings 
in additional models of stroke, including permanent ischemic and hemorrhagic 
models of stroke, and in female and at risk populations, in order to expand the 
potential role of FSAP in general stroke pathophysiology. Further experiments with 
NMDA injection model in FSAP-/- mice would also help dissect the in-vivo protective 
of FSAP against excitotoxic injury. Also, since FSAP is known to modulate 
neutrophils infiltration, it would be necessary to analyze their role in the observed 
effects. Furthermore, experiments with the proposed humanized FSAP-MI mice in our 
lab would much more closely resemble the clinical situation and give a better 
understanding role of FSAP in ischemic brain. 
Developing agents, which mimick the neuroprotective effect of FSAP or 
enhance the circulating FSAP activity could help minimize the ischemic stroke 
severity in human carriers of Marburg I SNP. Additionally, due to the ability of FSAP 
to modulate post stroke inflammation and tPA/NMDA excitotoxicity, FSAP 
mimicking drugs could improve the therapeutic window for tPA administration 
thereby benefiting all stroke patients.  
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Factor Seven Activating Protease (FSAP) is a circulating protease with a role 
in coagulation, fibrinolysis and inflammation. The FSAP-Marburg I polymorphism, 
with low proteolytic activity, is associated with an increased risk of stroke and late 
complications of carotid stenosis in humans. We recently showed that FSAP antigen 
and activity levels are elevated in patients with Ischemic Stroke. In order to find a 
mechanistic explanation for this we have investigated the effect of FSAP on primary 
mouse brain microvascular endothelial cells, astrocytes and neurons. We demonstrate 
that FSAP can regulate endothelial permeability in an in-vitro model of the blood 
brain barrier (BBB) by stabilizing junctional localization of ZO-1 and by preventing 
the opening of the endothelial tight junctions after oxygen glucose deprivation 
(OGD)/reoxygenation.  Furthermore, FSAP can cross the BBB and exert a protective 
effect on cortical astrocytes and neurons exposed to conditions mimicking stroke by 
activating the PI3K-Akt pathway. This protective effect was mediated by PAR-1 
dependent activation of Akt pathway and dependent on its proteolytic activity.  In a 
mouse in-situ thromboembolic stroke model, we observed that infarction volumes at 
24 hours were significantly larger in FSAP-/- mice and neurological score worse. 
However, no difference was observed in the either cerebral reperfusion or cerebral 
vasculature. Increased FSAP antigen and activity levels were detected in WT mice 
after stroke in accordance with the clinical findings. In the absence of endogenous 
FSAP, there was a tendency towards a pro-inflammatory phenotype post stroke. Also, 
the lack of FSAP after stroke resulted in decreased Akt phosphorylation and Bcl-2 
levels while increased levels of p53 were observed.  Thus, from the data presented in 
this thesis, we propose that FSAP is a novel neuroprotective agent of the 
neurovascular unit and loss of FSAP activity could suggest the possible mechanism 
which leads to less protection in Marburg I polymorphism patients. 
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Die Faktor VII-aktivierende Protease (FSAP) ist eine zirkulierende Protease 
mit einer Rolle in der Koagulation, der Fibrinolyse und in Entzündungsprozessen. Der 
FSAP-Marburg-I-Polymorphismus, ohne proteolytisch Aktivität ist mit einem 
erhöhten Risiko für Hirn-Infarkte und späteren Komplikationen wie Karotisstenosen 
assoziiert. Wir zeigen, dass FSAP-Antigen und -Aktivität in Patienten mit 
ischämischem Schlaganfall erhöht sind. Um eine mechanistische Erklärung dafür zu 
finden, haben wir die Wirkung von FSAP auf primäre mikrovaskuläre Hirn-
Endothelzellen, Astrozyten und Neuronen untersucht. In dieser Studie zeigen wir, 
dass FSAP die endotheliale Permeabilität in einem in-vitro-Modell der Blut-Hirn-
Schranke (BBB) durch Stabilisierung der junktionalen Lokalisierung von ZO- 1 und 
durch die Öffnung der endothelialen tight-junctions nach Sauerstoff-Glucose-
Deprivation (OGD)/ Reoxygenierung verhindern regulieren bzw kann. Darüber 
hinaus kann FSAP die BBB überqueren und somit eine schützende Wirkung auf 
kortikale Astrozyten und Neuronen ausüben, die einem Schlaganfall nach Aktivierung 
des PI3K-Akt-Signalweges ausgesetzt sind. Dieser schützende Effekt wird durch 
PAR-1-abhängige Aktivierung des Akt-Signalweges vermittelt. In einem in-situ 
thromboembolischen Schlaganfall-Modell der Maus beobachteten wir, dass das 
Infarktvolumen nach 24 Stunden deutlich größer und das neurologische Ergebnis in 
FSAP-/- Mäusen deutlich schlechter war. Es wurde kein Unterschied in der zerebralen 
Reperfusion oder in zerebralen Gefäßen beobachtet. In WT-Mäusen wurde mehr 
FSAP-Antigen und eine erhöhte FSAP-Aktivität festgestellt. In Abwesenheit von 
endogenem FSAP gab es eine Tendenz hin zu einem pro-inflammatorischen Phänotyp 
nach einem Schlaganfall . Auch das Fehlen von FSAP nach einem Schlaganfall führte 
zu einer verringerten Akt- Phosphorylierung und veringerten Bcl-2-Werten während 
erhöhte p53-Werte beobachtet wurden. So gibes eine neue Rolle für FSAP als 
neuroprotektives Agens in der neurovaskulären Einheit und der Verlust der FSAP-
Aktivität könnte eine mögliche Ursache des geringeren Schutzes in Marburg-I-
Polymorphismus Patienten sein. 
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AKT Protein Kinase B ELISA Enzyme-linked immunosorbent 
assay  
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid FBS Fetal Bovin Serum 
APC Activated Protein C FKHR forkhead transcription factor Foxo1 
APO Aprotinin FSAP Factor VII activating protease 
ARA-C cytosine arabinoside FV Factor V 
BBB Blood Brain Barrier FVIII Factor VIII 
BDNF Brain-derived neurotrophic factor GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
bFGF basic Fibroblast growth factor GFAP Glial fibrillary acidic protein 
BSA Bovine Serum Albumin GPCRs G protein-coupled receptors 
CNS Central Nervous System GS  Glutamine synthetase 
ct Threshold cycles GSK3β Glycogen synthase kinase 3 beta 
DIV Days in-vitro H2O2 Hyrogen Peroxide 
DMEM Dulbecco's modified Eagle's 
medium HBSS Hank's Balanced Salt Solution 
DMSO Dimethyl sulfoxide HMWK High-molecular-weight kininogen 
DWI Diffusion-weighted imaging  HT Hyper tension 
ECs Endothelial Cells ICAM Intercellular Adhesion Molecule 
EDTA Ethylenediaminetetraacetic acid IL Interlukin 
EGF Epidermal growth factor LDH Lactate dehydrogenase 
LSF  Laser Speckle Flowmetry NO Nitric Oxide 
MCA Middle Cerebral Artery OGD Oxygen Glucose Deprivation 
MCAO Middle Cerebral Artery Occlusion PAR Protease activated receptor 
MDM2 Mouse double minute 2 homolog PBS Phosphate buffered saline 
MLCK Myosin light-chain kinase PCR polymerase chain reaction 
MMP Matrix metalloproteinases PDGF BB platelet-derived growth factor 
MRA Magnetic resonance angiography PDK-1 Pyruvate dehydrogenase lipoamide kinase isozyme 1 
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MRI Magnetic resonance imaging PECAM Platelet endothelial cell 
adhesion molecule 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide PI3K Phosphoinositide 3-kinase 
Na3VO4 Sodium orthovanadate pMBMECs primary mouse brain microvascular endothelial cells 
NaCl Sodium Choride PPACK D-Phenylalanyl-L-prolyl-L-
arginine chloromethyl ketone 
NaF Sodium Floride PTEN Phosphatase and tensin homolog 
NaN3 Sodium Azide PVDF Polyvinylidene difluoride 
NaPyr Sodium Pyruvate ROS Reactive oxygen species  
NEAA Non-Essential Amino Acid SNP Single Nucleotide - polymorphism 
NeuN Neuronal Nuclei STAT Signal Transducer and Activator of Transcription 
NGF Nerve growth factor TBS Tris buffered saline 
NMDA N-Methyl-D-aspartate TdT terminal deoxynucleotidyl transferase 
LSF  Laser Speckle Flowmetry NO Nitric Oxide 
TEER Trans-Endothelial Electrical Resistance uPA Urokinase 
TFPI Tissue factor pathway inhibitor VCAM Vascular cell adhesion protein  
TGFβ-1 Transforming growth factor beta 1 VEGF Vascular endothelial growth factor 
TIA transient ischemic attack  ZO-1 Zona Occludens -1  
TMB  3,3',5,5'-Tetramethylbenzidine    
TNFα Tumor necrosis factor alpha   
TOF Time of Flight   
tPA Tissue plasminogen activator   
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling 
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1. List of devices used  
Product  Company 
BD GasPak ™  EZ Container Systems BD Biosciences, CA, USA 
Bruker PharmaScan 7.0 T, 16 cm Bruker Corportation, Germany 
Dissecting microscope: Leica S4E Leica Microsystems, Wetzlar, Germany 
Fluorescence microscope: Leica DMRB Leica Microsystems, Wetzlar, Germany 
GraphPad Prism 6 GraphPad Software, Inc., La Jolla, CA, 
USA 
Innova CO2 incubator CO-48  New Brunswick Scientific, NJ, USA 
Metamorph Imaging software 7.0 Molecular Devices, Downingtown, PA, 
USA 
Microplate reader EL808 Biotek Instruments, Winooski, OR, USA 
 
2. Reagents 
Product  Company 
2-Mercaptoethanol Carl Roth, Karlsruhe, Germany 
2-Propanol Carl Roth, Karlsruhe, Germany 
3,3,5,5-tetramethylbenzidine (TMB) EUROPA (Cambridge, UK) 
Acetic acid Carl Roth, Karlsruhe, Germany 
Acetone 99,8% Merck, Darmstadt, Germany 
Agarose Molecular Probes, Leiden, The 
Netherlands 
Arginine Sigma-Aldrich Chemie, Munich, 
Germany 
Bovine serum albumin (BSA) Sigma-Aldrich Chemie, Munich, 
Germany 
Calcium chloride Carl Roth, Karlsruhe, Germany 
DAPI Linaris, Wertheim, Germany 
Dry milk, fat-free Sigma-Aldrich Chemie, Munich, 
Germany 
Dulbecco’s modified eagle medium (D-
MEM) 
 
Invitrogen, Karsruhe, Germany 
Chapter 12. Appendix 
_____________________________________________________________________ 
 - 92 - 
Dulbecco’s modified eagle medium (D-
MEM) F12 
Invitrogen, Karsruhe, Germany 
Dulbecco’s modified eagle medium (D-
MEM) without Glucose 
Invitrogen, Karsruhe, Germany 
Dulbecco‟s phosphate buffered saline 
(PBS) 
PAA Laboratories, Pasching, Austria 
Ethanol Riedel-de Haën Sigma-Aldrich, Seelsze, 
Germany 
Fetal calf serum (FCS) Invitrogen, Karsruhe, Germany 
FITC dextran 30 kDA Invitrogen (Karlsruhe, Germany) 
Formalin solution (PFA) Carl Roth, Karlsruhe, Germany 
Gelatin 2%  solution Invitrogen (Karlsruhe, Germany) 
Glucose Carl Roth, Karlsruhe, Germany 
Glycerol Sigma-Aldrich Chemie, Munich, 
Germany 
Glycine Sigma-Aldrich Chemie, Munich, 
Germany 
Hank’s Balanced Salt Solution Invitrogen (Karlsruhe, Germany) 
Horse Serum Invitrogen (Karlsruhe, Germany) 
Hydrogen Peroxide 30% (H2O2) Merck, Darmstadt, Germany 
Isopropanol Carl Roth, Karlsruhe, Germany 
Laminin Invitrogen (Karlsruhe, Germany) 
Lysine Sigma-Aldrich Chemie, Munich, 
Germany 
Methanol Carl Roth, Karlsruhe, Germany 
MTT  Sigma-Aldrich Chemie, Munich, 
Germany 
NMDA Sigma-Aldrich Chemie, Munich, 
Germany 
PageRuler Prestained Protein Ladder Fermentas (St. Leon-Rot, Germany) 
Penicillin / Streptomycin Invitrogen, Karsruhe, Germany 
Plasminogen From blood of healthy volunteers 
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Poly-D-Lysine Sigma-Aldrich Chemie, Munich, 
Germany 
Poly-L-Lysine Sigma-Aldrich Chemie, Munich, 
Germany 
RNeasy Mini Kit Sigma-Aldrich Chemie, Munich, 
Germany 
Sodium acetate Carl Roth, Karlsruhe, Germany 
Sodium chloride 0,9% (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium chloride solution Carl Roth, Karlsruhe, Germany 
Sodium citrate Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
TEMED Carl Roth, Karlsruhe, Germany 
Tissue plasminogen activator  (Activase® 
(Alteplase)) 
Genentech, Inc., CA., USA 
Triton X-100 Carl Roth, Karlsruhe, Germany 
Tween 20 Sigma-Aldrich Chemie, Munich, 
Germany 
Tween 80 Sigma-Aldrich Chemie, Munich, 
Germany 
Vectashield mounting medium H 1000 
for 
Fluorescence 
Vector Laboratories, Burlington, CA, 
USA 
All other chemicals were obtained from Sigma (Munich, Germany) or Roth 
(Karlsruhe, Germany). 
 
3. Primer sequence of oligonucleotides used for quantitative realtime PCR 
Gene Primer Sequence 
COX-2 Forward ATGGTAGAAGTTGGAGCACCA 
COX-2 Reverse GGAGCGGGAAGAACTTGCA 
GADPH Reverse CGGCCAAATCCGTTCACACCGA 
GAPDH Forward CGCCACCAGTTCGCCATGGA 
IL-10 Forward GCTCTTACTGACTGGCATGAG 
IL-10 Reverse CGCAGCTCTAGGAGCATGTG 
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IL-4 Forward ACAGGAGAAGGGACGCCAT 
IL-4 Reverse GAAGCCCTACAGACGAGCTCA 
IL-6 Forward ACAACGATGATGCACTTGCAGA 
IL-6 Reverse TCCAGGTAGCTATGGTACTCCA 
iNOS - Forward CAGGCCAATGGCCGTGA 
iNOS - Reverse TAGTTCAGCATCTCCTGGTGA 
TNF alpha Forward CCCTCACACTCAGATCATCTTCT 
TNF alpha Reverse GCTACGACGTGGGCTACAG 
 
4. Primary and secondary antibodies for Western blotting 
 
Antibody  Species Isotype  Source Dilution 
Anti- pAKT Rabbit Polyclonal Cell Signaling Technology 
Inc., USA 
1:1000 
Anti- Total Akt Rabbit Polyclonal Cell Signaling Technology 
Inc., USA 
1:1000 
Anti- β-Actin Rabbit Polyclonal Cell Signaling Technology 
Inc., USA 
1:1000 
Anti- p53 Rabbit Polyclonal Cell Signaling Technology 
Inc., USA 
1:1000 
Anti- Bcl-2 Rabbit Polyclonal Cell Signaling Technology 
Inc., USA 
1:1000 
Anti- GAPDH Rabbit Polyclonal Cell Signaling Technology 
Inc., USA 
1:1000 
Anti- FSAP 
(MENEW) 
Rabbit Polyclonal A gift from Dr. Michael 
Etscheid (Langen) 
1:1000 
Anti- 
Rabbit POD  
Swine Polyclonal DAKO, Hamburg, Germany 1:2000 
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5. Antibodies used for staining  
 
Antibody  Species Isotype  Source Dilution 
Anti- GFAP Mouse Monoclonal Millipore, Billerica, MA, USA 1:400 
Anti- NeuN Mouse Monoclonal Millipore, Billerica, MA, USA 1:400 
Anti- ZO-1 Rabbit Polyclonal Invitrogen (Switzerland) 1:100 
Alexa Fluor 488- 
Anti Rabbit 
Goat Polyclonal  Molecular Probes, Eugene, 
OR, USA 
1:1000 
Alexa Furo 488 – 
Anti mouse 
Goat Polyclonal Molecular Probes, Eugene, 
OR, USA 
1:1000 
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